<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FLUVOXAMINE MALEATE- fluvoxamine maleateÂ tablet, film coatedÂ </strong><br>NCS HealthCare of KY, Inc dba Vangard Labs<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use fluvoxamine maleate tablets USP safely and effectively.  See full prescribing information for fluvoxamine maleate tablets USP.<br><br>Fluvoxamine maleate tablets USP, for oral use<br>Initial U.S. Approval: 1994</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">Warning: Suicidality and Antidepressants</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<p class="Highlighta"><span class="Bold">Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> and other psychiatric disorders. Fluvoxamine maleate tablets are not approved for use in pediatric patients except those with <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">obsessive compulsive disorder</span> (<a href="#LINK_6e4d7b0d-4f91-48a9-a17c-a75415c80d10">5.1</a>).</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Indications and Usage, Long-Term Use (<a href="#LINK_94699063-1370-4649-95b5-e9dcbbf41143">1.1</a>)                                                                        4/2008 </p>
<p class="Highlighta">Warnings and Precautions, Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> (<a href="#LINK_a38970d6-c303-4089-bf6e-49f0f281a2bb">5.8</a>, <a href="#LINK_7373ae12-0e72-4d83-b8d3-d0c44ebfa0c7">5.10</a>)                                                   4/2008 </p>
<p class="Highlighta">Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> or <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)-Like Reactions (<a href="#LINK_63c287fc-8a3a-4736-9d90-e2b4c0573137">5.3</a>)                                                                                                                        2/2009 </p>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">Warning: Suicidality and Antidepressants</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<p class="Highlighta"><span class="Bold">Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> and other psychiatric disorders. Fluvoxamine maleate tablets are not approved for use in pediatric patients except those with <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">obsessive compulsive disorder</span> (<a href="#LINK_6e4d7b0d-4f91-48a9-a17c-a75415c80d10">5.1</a>).</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Fluvoxamine maleate tablets are indicated for the treatment of obsessions and compulsions in patients with <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">obsessive compulsive disorder</span> (OCD) (<a href="#LINK_7b774beb-3aa4-4d43-bb54-25f74ad0e652">1</a>).  </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disk">
<li>Adults: Recommended starting dose is 50 mg at bedtime, with increases of 50 mg every 4 to 7 days as tolerated to maximum effect, not to exceed 300 mg/day. Daily doses over 100 mg should be divided (<a href="#LINK_0a97c798-48e8-4c97-b2c8-f71fff2315a3">2.1</a>). </li>
<li>Children and adolescents (8 to 17 years): Recommended starting dose is 25 mg at bedtime, with increases of 25 mg every 4 to 7 days as tolerated to maximum effect, not to exceed 200 mg/day (8 to 11 years) or 300 mg/day (12 to 17 years). Daily doses over 50 mg should be divided (<a href="#LINK_6e621988-2376-4efa-b3b3-d91508c2b3c5">2.2</a>). </li>
<li>Hepatically impaired: Decreased clearance may require modified dose and titration (<a href="#LINK_6a36a31f-567c-4cf8-8542-564e2947e08f">2.3</a>). </li>
<li>Discontinuation: Gradual dose reduction is recommended (<a href="#LINK_df932769-d555-4daa-914e-1c579426f9b9">2.7</a>, see <span class="Bold">Warnings and </span><span class="Bold">Precautions</span> [<a href="#LINK_31f8f254-94b1-432c-89fe-e59ecf6c8352">5.9</a>]). </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disk"><li> 25 mg Tablets, 50 mg Tablets, and 100 mg Tablets (<a href="#LINK_dea28109-eefe-4980-90dc-00d543657063">3</a>) </li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disk">
<li>Coadministration of tizanidine, thioridazine, alosetron, pimozide (<a href="#LINK_e4b468a0-af7f-43bc-a743-e16338cff18a">4</a>) </li>
<li>Use of MAOIs concomitantly with or within 14 days of treatment with fluvoxamine maleate tablets (<a href="#LINK_e4b468a0-af7f-43bc-a743-e16338cff18a">4</a>) </li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disk">
<li>
<span class="Italics">Suicidality:</span> Monitor for clinical worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> risk (<a href="#LINK_6e4d7b0d-4f91-48a9-a17c-a75415c80d10">5.1</a>). </li>
<li>
<span class="Italics">Bipolar disorder:</span> Screen for bipolar disorder (<a href="#LINK_6e4d7b0d-4f91-48a9-a17c-a75415c80d10">5.1</a>). </li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> or <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)-Like Reactions:</span> <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> or NMS-like reactions have been reported with SSRIs and SNRIs. Discontinue fluvoxamine maleate tablets and initiate supportive treatment (<a href="#LINK_63c287fc-8a3a-4736-9d90-e2b4c0573137">5.3</a>).</li>
<li>
<span class="Italics">Other potentially important drug interactions.</span><span class="Bold">Benzodiazepines:</span> Use with caution. Coadministration with diazepam is generally not advisable (<a href="#LINK_a38970d6-c303-4089-bf6e-49f0f281a2bb">5.8</a>). <span class="Bold">Clozapine:</span> Clozapine levels may be increased and produce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (<a href="#LINK_a38970d6-c303-4089-bf6e-49f0f281a2bb">5.8</a>). <span class="Bold">Methadone:</span> Coadministration may produce opioid <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>. Discontinuation of fluvoxamine may produce opioid withdrawal (<a href="#LINK_a38970d6-c303-4089-bf6e-49f0f281a2bb">5.8</a>). <span class="Bold">Mexiletine:</span> Monitor serum mexiletine levels (<a href="#LINK_a38970d6-c303-4089-bf6e-49f0f281a2bb">5.8</a>). <span class="Bold">Ramelteon:</span> Should not be used in combination with fluvoxamine (<a href="#LINK_a38970d6-c303-4089-bf6e-49f0f281a2bb">5.8</a>). <span class="Bold">Theophylline:</span> Clearance decreased; reduce theophylline dose by one-third (<a href="#LINK_a38970d6-c303-4089-bf6e-49f0f281a2bb">5.8</a>). <span class="Bold">Warfarin:</span> Plasma concentrations increased and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> times prolonged; monitor <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time and adjust warfarin dose accordingly (<a href="#LINK_a38970d6-c303-4089-bf6e-49f0f281a2bb">5.8</a>). <span class="Bold">Other Drugs Affecting Hemostasis:</span> Increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation (<a href="#LINK_a38970d6-c303-4089-bf6e-49f0f281a2bb">5.8</a>, <a href="#LINK_7373ae12-0e72-4d83-b8d3-d0c44ebfa0c7">5.10</a>). See <span class="Bold">Contraindications</span> (<a href="#LINK_e4b468a0-af7f-43bc-a743-e16338cff18a">4</a>). </li>
<li>
<span class="Italics">Discontinuation:</span> Symptoms associated with discontinuation have been reported (<a href="#LINK_31f8f254-94b1-432c-89fe-e59ecf6c8352">5.9</a>). Abrupt discontinuation not recommended. See <span class="Bold">Dosage And Administration</span> (<a href="#LINK_df932769-d555-4daa-914e-1c579426f9b9">2.7</a>). </li>
<li>
<span class="Italics">Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span></span> has occurred (<a href="#LINK_26d996aa-0b03-4e1c-b96c-d30947e06763">5.11</a>). </li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>:</span> Avoid administering fluvoxamine in patients with unstable <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>; monitor patients with controlled <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>; discontinue treatment if <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> occur or frequency increases (<a href="#LINK_3e1b2dda-a2a4-43f8-b1e0-910526b443a8">5.12</a>). </li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span>:</span> May occur with SSRIs and SNRIs, including fluvoxamine maleate tablets. The elderly may be at increased risk. Consider discontinuing in patients with symptomatic <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> (<a href="#LINK_4a5cf584-a2e0-4fd9-9e2e-c7434d11fd68">5.13</a>). </li>
<li>
<span class="Italics">Concomitant illness:</span> Use caution in patients with diseases or conditions that affect hemodynamic responses or metabolism (<a href="#LINK_deb471d3-574d-41d0-bead-50e4154b3fc4">5.14</a>). Patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span> may require a lower starting dose and slower titration (<a href="#LINK_6a36a31f-567c-4cf8-8542-564e2947e08f">2.3</a>). </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><ul class="Disk"><li> Most common reactions in controlled trials with adult OCD and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> patients (incidence â‰¥ 5% and at least twice that for placebo) were <span class="Italics"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, </span><span class="Italics"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">abnormal ejaculation</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>,</span> and <span class="Italics"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></span> (<a href="#LINK_d9c3dabb-fa47-4972-9648-3a62ac14e7f2">6.2</a>). Using the above rule, the following events were also identified: <span class="Italics"><span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">anorgasmia</span>, decreased libido, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>,</span> and <span class="Italics"><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span></span> in patients with OCD; and <span class="Italics"><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, </span><span class="Italics"><span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>,</span> and <span class="Italics"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></span> in pediatric patients with OCD. <br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact TEVA USA, PHARMACOVIGILANCE at 1-888-838-2872, X6351 or drug.safety@tevausa.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span>
</li></ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<p class="Highlighta">Drug Interactions (not described in Contraindications or Warnings And Precautions) include the following:  </p>
<p class="Highlighta"><span class="Italics">Drugs Inhibiting or Metabolized by Cytochrome P450:</span> Fluvoxamine inhibits several cytochrome P450 isoenzymes (CYP1A2, CYP2C9, CYP3A4, and CYP2C19). <span class="Bold">Carbamazepine:</span> Elevated carbamazepine levels and symptoms of toxicity with coadministration (<a href="#LINK_7be4d217-5c07-4193-a918-de970adc431d">7.2</a>). <span class="Bold">Sumatriptan:</span> Rare postmarketing reports of <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, and <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span> following use of an SSRI and sumatriptan. Monitor appropriately if concomitant treatment is clinically warranted (<a href="#LINK_7be4d217-5c07-4193-a918-de970adc431d">7.2</a>). <span class="Bold">Tacrine:</span> Coadministration increased tacrine C<span class="Sub">max</span> and AUC five- and eight-fold and caused <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (<a href="#LINK_7be4d217-5c07-4193-a918-de970adc431d">7.2</a>). <span class="Bold">Tricyclic Antidepressants (TCAs):</span> Coadministration significantly increased plasma TCA levels. Use caution; monitor plasma TCA levels; reduce TCA dose if indicated (<a href="#LINK_7be4d217-5c07-4193-a918-de970adc431d">7.2</a>). <span class="Bold">Tryptophan:</span> Severe <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> with coadministration (<a href="#LINK_7be4d217-5c07-4193-a918-de970adc431d">7.2</a>). <span class="Bold">Diltiazem:</span> <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> with coadministration (<a href="#LINK_5c5c5d90-be3a-426e-85d4-ad9263ead085">7.3</a>). <span class="Bold">Propranolol or metoprolol:</span> Reduce dose if coadministered and titrate more cautiously (<a href="#LINK_5c5c5d90-be3a-426e-85d4-ad9263ead085">7.3</a>).  </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<p class="Highlighta">Specific populations not discussed in <span class="Bold">Dosage and Administration</span> or <span class="Bold">Warnings and Precautions </span>include:  </p>
<ul class="Disk">
<li>Pregnancy: Consider both potential risks and benefits when treating a pregnant woman. Infants exposed to SSRIs late in pregnancy have developed various complications and may be at risk for persistent <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> of the newborn (PPHN). Consider tapering during the third trimester (<a href="#LINK_98701055-f6ff-4930-ba54-e12bc7a2e3da">2.4</a>, <a href="#LINK_4d42ec68-2e52-4496-9a7c-4127291a917b">8.1</a>). </li>
<li>Nursing mothers: Fluvoxamine is secreted in human breast milk (<a href="#LINK_4d42ec68-2e52-4496-9a7c-4127291a917b">8.3</a>). </li>
<li>Pediatric: Monitor weight and growth; effects of long-term use on growth, cognitive behavioral development, and maturation have not been studied (<a href="#LINK_4dd006ec-bb5f-47b7-aeb3-152dec0fa4fd">8.4</a>). </li>
<li>Geriatric: Use of a lower starting dose may be warranted. Titrate slowly during initiation of therapy (<a href="#LINK_6a36a31f-567c-4cf8-8542-564e2947e08f">2.3</a>, <a href="#LINK_2e4b9598-daae-4158-97d1-b5d0403803f7">8.5</a>). </li>
<li>Smokers: Smokers had a 25% increase in fluvoxamine metabolism (<a href="#LINK_edf6e6d5-6668-42ea-bfc0-256767c997ee">7.4</a>). </li>
</ul>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 5/2010</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc"><span class="XmChange">1.1</span> Obsessive-Compulsive Disorder</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Adults</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Pediatric Population (Children and Adolescents)</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Elderly or Hepatically Impaired Patients</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Pregnant Women During the Third Trimester</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Switching Patients to or From a Monoamine Oxidase Inhibitor</a></h2>
<h2><a href="#section-2.6" class="toc">2.7 Discontinuation of Treatment With Fluvoxamine Maleate Tablets USP</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Potential for Monoamine Oxidase Inhibitors Interaction</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> or <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)-Like Reactions</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Potential Thioridazine Interaction</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Potential Tizanidine Interaction</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Potential Pimozide Interaction</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Potential Alosetron Interaction</a></h2>
<h2><a href="#section-5.8" class="toc"><span class="XmChange">5.8</span> Other Potentially Important Drug Interactions</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Discontinuation of Treatment With Fluvoxamine Maleate Tablets</a></h2>
<h2><a href="#section-5.10" class="toc"><span class="XmChange">5.10</span> Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></a></h2>
<h2><a href="#section-5.13" class="toc">5.13 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></a></h2>
<h2><a href="#section-5.14" class="toc">5.14 Use in Patients With Concomitant Illness</a></h2>
<h2><a href="#section-5.15" class="toc">5.15 Laboratory Tests</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Adverse Reactions Leading to Treatment Discontinuation</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Incidence in Controlled Trials</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Other Adverse Reactions in OCD Pediatric Population</a></h2>
<h2><a href="#section-6.4" class="toc">6.4 Male and Female <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">Sexual Dysfunction</span> With SSRIs</a></h2>
<h2><a href="#section-6.5" class="toc">6.5 Vital Sign Changes</a></h2>
<h2><a href="#section-6.6" class="toc">6.6 Laboratory Changes</a></h2>
<h2><a href="#section-6.7" class="toc">6.7 ECG Changes</a></h2>
<h2><a href="#section-6.8" class="toc">6.8 Other Reactions Observed During the Premarketing Evaluation of Fluvoxamine Maleate Tablets</a></h2>
<h2><a href="#section-6.9" class="toc">6.9 Postmarketing Reports</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 CNS Active Drugs</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Other Drugs</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Effects of Smoking on Fluvoxamine Metabolism</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Electroconvulsive Therapy (ECT)</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled Substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.2 Abuse</a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-10.1" class="toc">10.1 Human Experience</a></h2>
<h2><a href="#section-10.2" class="toc">10.2 Management of Overdosage</a></h2>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.1 Adult OCD Studies</a></h2>
<h2><a href="#section-14.2" class="toc">14.3 Pediatric OCD Study</a></h2>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-15.2" class="toc">16.2 Storage</a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</a></h2>
<h2><a href="#section-16.2" class="toc">17.2 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></a></h2>
<h2><a href="#section-16.3" class="toc">17.3 Interference With Cognitive or Motor Performance</a></h2>
<h2><a href="#section-16.4" class="toc">17.4 Pregnancy</a></h2>
<h2><a href="#section-16.5" class="toc">17.5 Nursing</a></h2>
<h2><a href="#section-16.6" class="toc">17.6 Concomitant Medication</a></h2>
<h2><a href="#section-16.7" class="toc">17.7 Alcohol</a></h2>
<h2><a href="#section-16.8" class="toc">17.8 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></a></h2>
<h2><a href="#section-16.9" class="toc">17.9 FDA-Approved Medication Guide</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="LINK_642a1ea5-81d9-4a67-a5a9-aba16bf21e40"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">S</span><span class="Bold">UICIDALITY AND ANTIDEPRESSANT DRUGS</span></p>
<p><span class="Bold">Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive</span><span class="Bold">disorder (MDD) and other psychiatric disorders. Anyone considering the use of fluvoxamine maleate tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older.</span><span class="Bold"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and certain other psychiatric disorders are themselves associated with increases in the risk of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Fluvoxamine maleate tablets are not approved for use in pediatric patients except for patients with <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">obsessive compulsive disorder</span> (OCD) (see WARNINGS AND PRECAUTIONS, Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk [<a href="#LINK_6e4d7b0d-4f91-48a9-a17c-a75415c80d10">5.1</a>]).</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_7b774beb-3aa4-4d43-bb54-25f74ad0e652"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_94699063-1370-4649-95b5-e9dcbbf41143"></a><a name="section-1.1"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange">1.1</span> Obsessive-Compulsive Disorder</h2>
<p class="First">Fluvoxamine maleate tablets are indicated for the treatment of obsessions and compulsions in patients with <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">obsessive compulsive disorder</span> (OCD), as defined in DSM-III-R or DSM-IV. The obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. </p>
<p><span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">Obsessive compulsive disorder</span> is characterized by recurrent and persistent ideas, thoughts, impulses or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. </p>
<p>The efficacy of fluvoxamine maleate tablets was established in three trials in outpatients with OCD: two 10 week trials in adults, and one 10 week trial in pediatric patients (ages 8 to 17) (see <span class="Bold">CLINICAL STUDIES</span> [<a href="#LINK_05592228-b2ad-4626-bea7-f8d300f3d62f">14</a>]). </p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_f69ad767-c928-4c6b-94be-fce1176de1b2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0a97c798-48e8-4c97-b2c8-f71fff2315a3"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Adults</h2>
<p class="First">The recommended starting dose for fluvoxamine maleate tablets USP in adult patients is 50 mg, administered as a single daily dose at bedtime. In the controlled clinical trials establishing the effectiveness of fluvoxamine maleate tablets USP in OCD, patients were titrated within a dose range of 100 to 300 mg/day. Consequently, the dose should be increased in 50 mg increments every 4 to 7 days, as tolerated, until maximum therapeutic benefit is achieved, not to exceed 300 mg per day. It is advisable that a total daily dose of more than 100 mg should be given in two divided doses. If the doses are not equal, the larger dose should be given at bedtime. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6e621988-2376-4efa-b3b3-d91508c2b3c5"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Pediatric Population (Children and Adolescents)</h2>
<p class="First">The recommended starting dose for fluvoxamine maleate tablets USP in pediatric populations (ages 8 to 17 years) is 25 mg, administered as a single daily dose at bedtime. In a controlled clinical trial establishing the effectiveness of fluvoxamine maleate tablets USP in OCD, pediatric patients (ages 8 to 17) were titrated within a dose range of 50 to 200 mg/day. Physicians should consider age and gender differences when dosing pediatric patients. The maximum dose in children up to age 11 should not exceed 200 mg/day. Therapeutic effect in female children may be achieved with lower doses. Dose adjustment in adolescents (up to the adult maximum dose of 300 mg) may be indicated to achieve therapeutic benefit. The dose should be increased in 25 mg increments every 4 to 7 days, as tolerated, until maximum therapeutic benefit is achieved. It is advisable that a total daily dose of more than 50 mg should be given in two divided doses. If the two divided doses are not equal, the larger dose should be given at bedtime.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6a36a31f-567c-4cf8-8542-564e2947e08f"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Elderly or Hepatically Impaired Patients</h2>
<p class="First">Elderly patients and those with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have been observed to have a decreased clearance of fluvoxamine maleate. Consequently, it may be appropriate to modify the initial dose and the subsequent dose titration for these patient groups. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_98701055-f6ff-4930-ba54-e12bc7a2e3da"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Pregnant Women During the Third Trimester</h2>
<p class="First">Neonates exposed to fluvoxamine maleate tablets USP and other SSRIs or SNRIs late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding and may be at risk for persistent <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> of the newborn (PPHN) (see <span class="Bold">USE IN SPECIFIC POPULATIONS</span> [<a href="#LINK_4d42ec68-2e52-4496-9a7c-4127291a917b">8.1</a>]). When treating pregnant women with fluvoxamine maleate tablets USP during the third trimester, the physician should carefully consider the potential risks and benefits of treatment. The physician may consider tapering fluvoxamine maleate tablets USP in the third trimester. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_cf6e2b10-0bef-4326-aae2-c53d80c2addf"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Switching Patients to or From a Monoamine Oxidase Inhibitor</h2>
<p class="First">At least 14 days should elapse between discontinuation of an MAOI and initiation of therapy with fluvoxamine maleate tablets USP. Similarly, at least 14 days should be allowed after stopping fluvoxamine maleate tablets USP before starting an MAOI.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_df932769-d555-4daa-914e-1c579426f9b9"></a><a name="section-2.6"></a><p></p>
<h2>2.7 Discontinuation of Treatment With Fluvoxamine Maleate Tablets USP</h2>
<p class="First">Symptoms associated with discontinuation of other SSRIs or SNRIs have been reported (see <span class="Bold">WARNINGS AND PRECAUTIONS</span> [<a href="#LINK_31f8f254-94b1-432c-89fe-e59ecf6c8352">5.9</a>]). Patients should be monitored for these symptoms when discontinuing treatment. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate. </p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_dea28109-eefe-4980-90dc-00d543657063"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Fluvoxamine maleate tablets USP are available as: </p>
<p>Tablets 25 mg: white, film-coated capsule-shaped tablets debossed â€œ93â€? on one side and â€œ72â€? on the other side</p>
<p>Tablets 50 mg: yellow, film-coated capsule-shaped tablets debossed â€œ93â€? on one side and scored between the two numbers, and debossed â€œ56â€? on the other side </p>
<p>Tablets 100 mg: pink to light-brick, film-coated capsule-shaped tablets debossed â€œ93â€? on one side and scored between the two numbers, and debossed â€œ57â€? on the other side</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_e4b468a0-af7f-43bc-a743-e16338cff18a"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Coadministration of tizanidine, thioridazine, alosetron, or pimozide with fluvoxamine maleate tablets is contraindicated (see <span class="Bold">WARNINGS AND PRECAUTIONS</span> [<a href="#LINK_87de6cd3-0b15-429c-9ef1-4f29e337db05">5.4 </a>to <a href="#LINK_51997691-e6f7-4af2-86bc-875010a13dc6">5.7</a>]). </p>
<p>The use of MAOIs concomitantly with or within 14 days of treatment with fluvoxamine maleate tablets is contraindicated (see <span class="Bold">WARNINGS AND PRECAUTIONS</span> [<a href="#LINK_d8a1ba75-9d20-4e7d-9f09-daf8f7da60d1">5.2</a>]). </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_d9ee8f37-7598-4021-bd6b-90ccfe7af386"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6e4d7b0d-4f91-48a9-a17c-a75415c80d10"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</h2>
<p class="First">Patients with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD), both adult and pediatric, may experience worsening of their <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or the emergence of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> is a known risk of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older. </p>
<p>The pooled analyses of placebo-controlled trials in children and adolescents with MDD, <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">obsessive compulsive disorder</span> (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1000 patients treated) are provided in <span class="Bold">Table 1</span>. </p>
<table border="1">
<caption><span>Table 1: DRUG-PLACEBO DIFFERENCES IN NUMBER OF CASES OF SUICIDALITY PER 1000 PATIENTS TREATED</span></caption>
<col>
<col>
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule" valign="bottom">Â <span class="Bold">Age Range </span>
</td>
<td class="Botrule Rrule">Â <span class="Bold">Increases Compared to Placebo </span>
</td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule">Â <span class="Bold">&lt; 18 </span>
</td>
<td class="Botrule Rrule">Â <span class="Bold">14</span><span class="Bold"> ADDITIONAL CASES</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â <span class="Bold">18 to 24</span>
</td>
<td class="Botrule Rrule" align="center">Â <span class="Bold">5</span><span class="Bold">ADDITIONAL CASES</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â <span class="Bold">Age Range </span>
</td>
<td class="Botrule Rrule">Â <span class="Bold">Decreases Compared to Placebo</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â <span class="Bold">25 to 64</span>
</td>
<td class="Botrule Rrule" align="center">Â <span class="Bold">1</span><span class="Bold"> FEWER CASE </span>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule">Â <span class="Bold">â‰¥</span><span class="Bold">65</span>
</td>
<td class="Botrule Rrule" align="center">Â <span class="Bold">6</span><span class="Bold"> FEWER CASES </span>
</td>
</tr>
</tbody>
</table>
<p>No <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> occurred in any of the pediatric trials. There were <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> in the adult trials, but the number was not sufficient to reach any conclusion about the drug effect on <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. </p>
<p>It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> that the use of antidepressants can delay the recurrence of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. </p>
<p><span class="Bold">All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.</span></p>
<p>The following symptoms, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, impulsivity, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">psychomotor restlessness</span>), <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, and <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, have been reported in adult and pediatric patients being treated with antidepressants for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality. </p>
<p>Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patientâ€™s presenting symptoms. </p>
<p>If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms (see <span class="Bold">DOSAGE AND ADMINISTRATION</span>, <span class="Bold">Discontinuation of Treatment With</span><span class="Bold">Fluvoxamine Maleate Tablets</span> [<a href="#LINK_31f8f254-94b1-432c-89fe-e59ecf6c8352">5.9</a>], for a description of the risks of discontinuation of fluvoxamine maleate tablets). </p>
<p><span class="Bold">Families and caregivers of patients being treated with antidepressants for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to healthcare providers. Such monitoring should include daily observation by families and caregivers.</span> Prescriptions for fluvoxamine maleate tablets should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. </p>
<p><span class="Bold">Screening Patients for Bipolar Disorder:</span> A major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episode</span> may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episode</span> in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span> should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, bipolar disorder, and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. It should be noted that fluvoxamine maleate tablets are not approved for use in treating <span class="product-label-link" type="condition" conceptid="436665" conceptname="Bipolar disorder">bipolar depression</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d8a1ba75-9d20-4e7d-9f09-daf8f7da60d1"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Potential for Monoamine Oxidase Inhibitors Interaction</h2>
<p class="First">In patients receiving another serotonin reuptake inhibitor drug in combination with monoamine oxidase inhibitors (MAOIs), there have been reports of serious, sometimes fatal, reactions including <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> with possible rapid fluctuations of vital signs, and <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> that include extreme <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> progressing to <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. These reactions have also been reported in patients who have discontinued that drug and have been started on an MAOI. Some cases presented with features resembling a <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> or <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span>. Therefore, fluvoxamine maleate tablets should not be used in combination with an MAOI, or within 14 days of discontinuing treatment with an MAOI. Similarly, at least 14 days should be allowed after stopping fluvoxamine maleate tablets before starting an MAOI (see <span class="Bold">DOSAGE AND ADMINISTRATION</span> [<a href="#LINK_cf6e2b10-0bef-4326-aae2-c53d80c2addf">2.5</a>] and <span class="Bold">CONTRAINDICATIONS</span> [<a href="#LINK_e4b468a0-af7f-43bc-a743-e16338cff18a">4</a>]). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_63c287fc-8a3a-4736-9d90-e2b4c0573137"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> or <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)-Like Reactions</h2>
<p class="First">The development of a potentially life-threatening <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> or <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)-like reactions have been reported with SNRIs and SSRIs alone, including fluvoxamine maleate tablet treatment, but particularly with concomitant use of serotonergic drugs (including triptans) with drugs which impair metabolism of serotonin (including MAOIs), or with antipsychotics or other dopamine antagonists. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> symptoms may include <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular aberrations (e.g., <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>) and/or <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>). <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span>, in its most severe form can resemble <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span>, which includes <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> with possible rapid fluctuation of vital signs, and <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span>. Patients should be monitored for the emergence of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> or NMS-like signs and symptoms.</p>
<p>The concomitant use of fluvoxamine maleate tablets with MAOIs intended to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> is contraindicated.</p>
<p>If concomitant treatment of fluvoxamine maleate tablets with a 5-hydroxytryptamine receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.</p>
<p>The concomitant use of fluvoxamine maleate tablets with serotonin precursors (such as tryptophan) is not recommended.</p>
<p>Treatment with fluvoxamine maleate tablets and any concomitant serotonergic or antidopaminergic agents, including antipsychotics, should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_87de6cd3-0b15-429c-9ef1-4f29e337db05"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Potential Thioridazine Interaction</h2>
<p class="First">The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentrations was evaluated in 10 male inpatients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased threefold following coadministration of fluvoxamine. </p>
<p>Thioridazine administration produces a dose-related prolongation of the QT<span class="Sub">c</span> interval, which is associated with serious <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, such as <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>-type <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>. It is likely that this experience underestimates the degree of risk that might occur with higher doses of thioridazine. Moreover, the effect of fluvoxamine may be even more pronounced when it is administered at higher doses. </p>
<p>Therefore, fluvoxamine and thioridazine should not be coadministered (see <span class="Bold">CONTRAINDICATIONS</span> [<a href="#LINK_e4b468a0-af7f-43bc-a743-e16338cff18a">4</a>]). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8581f9ea-ef79-4529-8aa2-84d6410677e9"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Potential Tizanidine Interaction</h2>
<p class="First">Fluvoxamine is a potent inhibitor of CYP1A2 and tizanidine is a CYP1A2 substrate. The effect of fluvoxamine (100 mg daily for 4 days) on the pharmacokinetics and pharmacodynamics of a single 4 mg dose of tizanidine has been studied in 10 healthy male subjects. Tizanidine C<span class="Sub">max</span> was increased approximately 12 fold (range 5 fold to 32 fold), elimination half-life was increased by almost 3 fold, and AUC increased 33 fold (range 14 fold to 103 fold). The mean maximal effect on blood pressure was a 35 mm Hg decrease in systolic blood pressure, a 20 mm Hg decrease in diastolic blood pressure, and a 4 beat/min decrease in heart rate. <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span> was significantly increased and performance on the psychomotor task was significantly impaired. Fluvoxamine and tizanidine should not be used together (see <span class="Bold">CONTRAINDICATIONS</span> [<a href="#LINK_e4b468a0-af7f-43bc-a743-e16338cff18a">4</a>]).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_065606d4-0c80-4551-9a56-12e3cc49eaf4"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Potential Pimozide Interaction</h2>
<p class="First">Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. An increased plasma concentration of pimozide causes QT prolongation and has been associated with <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>-type <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, sometimes fatal. As noted below, a substantial <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> has been observed for fluvoxamine in combination with alprazolam, a drug that is known to be metabolized by CYP3A4. Although it has not been definitively demonstrated that fluvoxamine is a potent CYP3A4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam. Consequently, it is recommended that fluvoxamine not be used in combination with pimozide (see <span class="Bold">CONTRAINDICATIONS</span> [<a href="#LINK_e4b468a0-af7f-43bc-a743-e16338cff18a">4</a>]). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_51997691-e6f7-4af2-86bc-875010a13dc6"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Potential Alosetron Interaction</h2>
<p class="First">Because alosetron is metabolized by a variety of hepatic CYP drug metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance of alosetron. Fluvoxamine is a known potent inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9, and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg to 200 mg a day for 16 days, with coadministration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentration (AUC) approximately 6 fold and prolonged the half-life by approximately 3 fold (see <span class="Bold">CONTRAINDICATIONS</span> [<a href="#LINK_e4b468a0-af7f-43bc-a743-e16338cff18a">4</a>] and LotronexÂ® (alosetron) package insert). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a38970d6-c303-4089-bf6e-49f0f281a2bb"></a><a name="section-5.8"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange">5.8</span> Other Potentially Important Drug Interactions</h2>
<p class="First"><span class="Bold"><span class="Italics">Benzodiazepines:</span></span> Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam, etc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine. The clearance of benzodiazepines metabolized by glucuronidation (e.g., lorazepam, oxazepam, temazepam) is unlikely to be affected by fluvoxamine. </p>
<p><span class="Bold">Alprazolam</span> - When fluvoxamine maleate (100 mg q.d.) and alprazolam (1 mg q.i.d.) were coadministered to steady state, plasma concentrations and other pharmacokinetic parameters (AUC, C<span class="Sub">max</span>, T<span class="Sub">Â½</span>) of alprazolam were approximately twice those observed when alprazolam was administered alone; oral clearance was reduced by about 50%. The elevated plasma alprazolam concentrations resulted in decreased psychomotor performance and memory. This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is coadministered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100 to 300 mg. If alprazolam is coadministered with fluvoxamine maleate tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended. No dosage adjustment is required for fluvoxamine maleate tablets. </p>
<p><span class="Bold">Diazepam</span> - The coadministration of fluvoxamine maleate tablets and diazepam is generally not advisable. Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic coadministration. </p>
<p>Evidence supporting the conclusion that it is inadvisable to coadminister fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam. In these subjects (N = 8), the clearance of diazepam was reduced by 65% and that of N-desmethyldiazepam to a level that was too low to measure over the course of the 2 week long study. </p>
<p>It is likely that this experience significantly underestimates the degree of accumulation that might occur with repeated diazepam administration. Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses. </p>
<p>Accordingly, diazepam and fluvoxamine should not ordinarily be coadministered. </p>
<p><span class="Bold"><span class="Italics">Clozapine</span></span> - Elevated serum levels of clozapine have been reported in patients taking fluvoxamine maleate and clozapine. Since clozapine-related <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> appear to be dose related, the risk of these adverse events may be higher when fluvoxamine and clozapine are coadministered. Patients should be closely monitored when fluvoxamine maleate and clozapine are used concurrently. </p>
<p><span class="Italics"><span class="Bold">Methadone</span></span> - Significantly increased methadone (plasma level:dose) ratios have been reported when fluvoxamine maleate was administered to patients receiving maintenance methadone treatment, with symptoms of opioid <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> in one patient. Opioid withdrawal symptoms were reported following fluvoxamine maleate discontinuation in another patient. </p>
<p><span class="Bold"><span class="Italics">Mexiletine:</span></span> The effect of steady-state fluvoxamine (50 mg b.i.d. for 7 days) on the single dose pharmacokinetics of mexiletine (200 mg) was evaluated in 6 healthy Japanese males. The clearance of mexiletine was reduced by 38% following coadministration with fluvoxamine compared to mexiletine alone. If fluvoxamine and mexiletine are coadministered, serum mexiletine levels should be monitored. </p>
<p><span class="Bold"><span class="Italics">Ramelteon: </span></span> When fluvoxamine 100 mg twice daily was administered for 3 days prior to single-dose coadministration of ramelteon 16 mg and fluvoxamine, the AUC for ramelteon increased approximately 190 fold and the C<span class="Sub">max</span> increased approximately 70 fold compared to ramelteon administered alone. Ramelteon should not be used in combination with fluvoxamine. </p>
<p><span class="Italics"><span class="Bold">Theophylline:</span></span> The effect of steady-state fluvoxamine (50 mg bid) on the pharmacokinetics of a single dose of theophylline (375 mg as 442 mg aminophylline) was evaluated in 12 healthy non-smoking, male volunteers. The clearance of theophylline was decreased approximately 3 fold. Therefore, if theophylline is coadministered with fluvoxamine maleate, its dose should be reduced to one-third of the usual daily maintenance dose and plasma concentrations of theophylline should be monitored. No dosage adjustment is required for fluvoxamine maleate tablets. </p>
<p><span class="Bold"><span class="Italics">Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.):</span></span> Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of the case-control and cohort design have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Thus, patients should be cautioned about the use of such drugs concurrently with fluvoxamine (see <span class="Bold">WARNINGS AND PRECAUTIONS</span>, <span class="Bold">Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></span> [<a href="#LINK_7373ae12-0e72-4d83-b8d3-d0c44ebfa0c7">5.10</a>]). </p>
<p><span class="Bold">Warfarin</span> - When fluvoxamine maleate (50 mg t.i.d.) was administered concomitantly with warfarin for two weeks, warfarin plasma concentrations increased by 98% and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> times were prolonged. Thus patients receiving oral anticoagulants and fluvoxamine maleate tablets should have their <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time monitored and their anticoagulant dose adjusted accordingly. No dosage adjustment is required for fluvoxamine maleate tablets. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_31f8f254-94b1-432c-89fe-e59ecf6c8352"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Discontinuation of Treatment With Fluvoxamine Maleate Tablets</h2>
<p class="First">During marketing of fluvoxamine maleate tablets and other SSRIs and SNRIs (serotonin and norepinephrine reuptake inhibitors), there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4311114" conceptname="Sensory disorder">sensory disturbances</span> (e.g., <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, such as <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">electric shock sensations</span>), <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>. While these events are generally self-limiting, there have been reports of serious discontinuation symptoms. </p>
<p>Patients should be monitored for these symptoms when discontinuing treatment with fluvoxamine maleate tablets. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate (see <span class="Bold">DOSAGE AND ADMINISTRATION</span> [<a href="#LINK_df932769-d555-4daa-914e-1c579426f9b9">2.7</a>]). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7373ae12-0e72-4d83-b8d3-d0c44ebfa0c7"></a><a name="section-5.10"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange">5.10</span> Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">SSRIs and SNRIs, including fluvoxamine maleate tablets, may increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events. Concomitant use of aspirin, non-steroidal anti-inflammatory drugs, warfarin, and other anticoagulants may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> events related to SSRIs and SNRIs have ranged from <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span>, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, and <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span> to life-threatening <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span>. </p>
<p>Patients should be cautioned about the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with the concomitant use of fluvoxamine maleate tablets and NSAIDs, aspirin, or other drugs that affect coagulation [see section <a href="#LINK_a38970d6-c303-4089-bf6e-49f0f281a2bb">5.8</a>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_26d996aa-0b03-4e1c-b96c-d30947e06763"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span></h2>
<p class="First">During premarketing studies involving primarily depressed patients, <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> or <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> occurred in approximately 1% of patients treated with fluvoxamine. In a ten week pediatric OCD study, 2 out of 57 patients (4%) treated with fluvoxamine experienced <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic reactions</span>, compared to none of 63 placebo patients. Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> has also been reported in a small proportion of patients with major <span class="product-label-link" type="condition" conceptid="444100" conceptname="Mood disorder">affective disorder</span> who were treated with other marketed antidepressants. As with all antidepressants, fluvoxamine maleate tablets should be used cautiously in patients with a history of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3e1b2dda-a2a4-43f8-b1e0-910526b443a8"></a><a name="section-5.12"></a><p></p>
<h2>5.12 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></h2>
<p class="First">During premarketing studies, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> were reported in 0.2% of fluvoxamine-treated patients. Caution is recommended when the drug is administered to patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span>. Fluvoxamine should be avoided in patients with unstable <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and patients with controlled <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> should be carefully monitored. Treatment with fluvoxamine should be discontinued if <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> occur or if <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency increases. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4a5cf584-a2e0-4fd9-9e2e-c7434d11fd68"></a><a name="section-5.13"></a><p></p>
<h2>5.13 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> may occur as a result of treatment with SSRIs and SNRIs, including fluvoxamine maleate tablets. In many cases, this <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> appears to be the result of the syndrome of inappropriate antidiuretic hormone (<span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span>). Cases with serum sodium lower than 110 mmol/L have been reported. Elderly patients may be at greater risk of developing <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> with SSRIs and SNRIs (see <span class="Bold">USE IN SPECIFIC POPULATIONS</span>, <span class="Bold">Ge</span><span class="Bold">riatric</span><span class="Bold">Use</span> [<a href="#LINK_2e4b9598-daae-4158-97d1-b5d0403803f7">8.5</a>]). Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. Discontinuation of fluvoxamine maleate tablets should be considered in patients with symptomatic <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> and appropriate medical intervention should be instituted. </p>
<p>Signs and symptoms of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, difficulty concentrating, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">unsteadiness</span>, which may lead to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span>. Signs and symptoms associated with more severe and/or acute cases have included <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_deb471d3-574d-41d0-bead-50e4154b3fc4"></a><a name="section-5.14"></a><p></p>
<h2>5.14 Use in Patients With Concomitant Illness</h2>
<p class="First">Closely monitored clinical experience with fluvoxamine maleate tablets in patients with concomitant systemic illness is limited. Caution is advised in administering fluvoxamine maleate tablets to patients with diseases or conditions that could affect hemodynamic responses or metabolism. </p>
<p>Fluvoxamine maleate tablets have not been evaluated or used to any appreciable extent in patients with a recent history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or unstable heart disease. Patients with these diagnoses were systematically excluded from many clinical studies during the product's premarketing testing. Evaluation of the electrocardiograms for patients with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or OCD who participated in premarketing studies revealed no differences between fluvoxamine and placebo in the emergence of clinically important ECG changes. </p>
<p><span class="Bold">Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span> - In patients with liver dysfunction, fluvoxamine clearance was decreased by approximately 30%. Patients with liver dysfunction should begin with a low dose of fluvoxamine maleate tablets and increase it slowly with careful monitoring.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="LINK_b7e69d5e-14d2-4e5a-b08d-d0fac30f5d16"></a><a name="section-5.15"></a><p></p>
<h2>5.15 Laboratory Tests</h2>
<p class="First">There are no specific laboratory tests recommended. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_bc026a01-722d-44ac-be7b-67154def9871"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_51dc4c2b-933c-48ef-b93b-27d33664ba9f"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Adverse Reactions Leading to Treatment Discontinuation</h2>
<p class="First">Of the 1087 OCD and depressed patients treated with fluvoxamine maleate in controlled clinical trials in North America, 22% discontinued due to an adverse reaction. Adverse reactions that led to discontinuation in at least 2% of fluvoxamine maleate-treated patients in these trials were: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (9%), <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (4%), <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (4%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (3%), and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (2% each). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d9c3dabb-fa47-4972-9648-3a62ac14e7f2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Incidence in Controlled Trials</h2>
<p class="First"><span class="Bold"><span class="Italics">Commonly Observed Adverse Reactions in Controlled Clinical Trials:</span></span> Fluvoxamine maleate tablets have been studied in 10 week short-term controlled trials of OCD (N = 320) and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (N = 1350). In general, adverse reaction rates were similar in the two data sets as well as in the pediatric OCD study. The most commonly observed adverse reactions associated with the use of fluvoxamine maleate tablets and likely to be drug-related (incidence of 5% or greater and at least twice that for placebo) derived from <span class="Bold">Table 2</span> were: <span class="Italics"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>,</span><span class="Italics"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">abnormal ejaculation</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>,</span> and <span class="Italics"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></span>. In a pool of two studies involving only patients with OCD, the following additional reactions were identified using the above rule: <span class="Italics"><span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">anorgasmia</span>, decreased libido, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>,</span> and <span class="Italics"><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span></span>. In a study of pediatric patients with OCD, the following additional reactions were identified using the above rule: <span class="Italics"><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>,</span><span class="Italics"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>,</span> and <span class="Italics"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></span>. </p>
<p><span class="Bold"><span class="Italics">Adverse Reactions Occurring at an Incidence of 1%:</span></span><span class="Bold">Table 2</span> enumerates adverse reactions that occurred in adults at a frequency of 1% or more, and were more frequent than in the placebo group, among patients treated with fluvoxamine maleate tablets in two short-term placebo controlled OCD trials (10 week) and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> trials (6 week) in which patients were dosed in a range of generally 100 to 300 mg/day. This table shows the percentage of patients in each group who had at least one occurrence of a reaction at some time during their treatment. Reported adverse reactions were classified using a standard COSTART-based Dictionary terminology. </p>
<p>The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors may differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and non-drug factors to the side-effect incidence rate in the population studied.</p>
<table border="1">
<caption><span>Table 2: TREATMENT-EMERGENT ADVERSE REACTION INCIDENCE RATES BY BODY SYSTEM IN ADULT OCD AND <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span> POPULATIONS COMBINED<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col width="34.7%">
<col width="31.1%">
<col width="34.2%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Reactions for which fluvoxamine maleate incidence was equal to or less than placebo are not listed in the table above.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">â€ </a></dt>
<dd>Includes â€œtoothache,â€? â€œtooth extraction and <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>,â€? and â€œcaries.â€?</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">â€¡</a></dt>
<dd>Mostly feeling warm, hot, or <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span>.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">Â§</a></dt>
<dd>Mostly â€œblurred vision.â€?</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">Â¶</a></dt>
<dd>Mostly â€œdelayed ejaculation.â€?</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">#</a></dt>
<dd>Incidence based on number of male patients.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Â <span class="Bold"></span>
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">Â <span class="Bold">Percentage of Patients Reporting Reaction</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center">Â <span class="Bold">BODY SYSTEM/ ADVERSE REACTION</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <span class="Bold">FLUVOXAMINE N = 892</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <span class="Bold">PLACEBO N = 778</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â <span class="Bold">BODY AS A WHOLE</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <span class="Bold">Â </span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <span class="Bold">Â </span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  22 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  20 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  14 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  6 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu Syndrome</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  3 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  2 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  2 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  1 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â <span class="Bold">CARDIOVASCULAR</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â  Â  </td>
<td class="Botrule Rrule" align="center" valign="top">Â  Â  </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  3 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  2 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â <span class="Bold">DIGESTIVE SYSTEM</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â  Â  </td>
<td class="Botrule Rrule" align="center" valign="top">Â  Â  </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  40 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  14 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  11 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  7 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  10 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  8 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  10 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  5 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  6 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  2 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  5 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  2 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  4 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  3 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="4122115" conceptname="Tooth disorder">Tooth Disorder</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">â€ </a>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â  3 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  1 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  2 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  1 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â <span class="Bold">NERVOUS SYSTEM</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â  Â  </td>
<td class="Botrule Rrule" align="center" valign="top">Â  Â  </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  22 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  8 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  21 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  10 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  14 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  10 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  12 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  5 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  11 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  6 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  5 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  1 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  5 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  3 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">Vasodilatation</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">â€¡</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â  3 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  1 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">Hypertonia</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  2 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  1 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  2 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  1 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  Decreased Libido </td>
<td class="Botrule Rrule" align="center" valign="top">Â  2 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  1 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  2 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  1 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  CNS Stimulation </td>
<td class="Botrule Rrule" align="center" valign="top">Â  2 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  1 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â <span class="Bold">RESPIRATORY SYSTEM</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â  Â  </td>
<td class="Botrule Rrule" align="center" valign="top">Â  Â  </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Infection</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  9 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  5 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  2 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  1 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">Yawn</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  2 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  0 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â <span class="Bold">SKIN</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â  Â  </td>
<td class="Botrule Rrule" align="center" valign="top">Â  Â  </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  7 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  3 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â <span class="Bold">SPECIAL SENSES</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â  Â  </td>
<td class="Botrule Rrule" align="center" valign="top">Â  Â  </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste Perversion</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  3 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  1 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">Amblyopia</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">Â§</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â  3 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  2 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â <span class="Bold">UROGENITAL</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â  Â  </td>
<td class="Botrule Rrule" align="center" valign="top">Â  Â  </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">Abnormal Ejaculation</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">Â¶</a><span class="Sup">,</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">#</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â  8 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  1 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary Frequency</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  3 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  2 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span> <a href="#footnote-6" class="Sup">#</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â  2 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  1 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">Anorgasmia</span> </td>
<td class="Botrule Rrule" align="center" valign="top">Â  2 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  0 </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span> </td>
<td class="Rrule" align="center" valign="top">Â  1 </td>
<td class="Botrule Rrule" align="center" valign="top">Â  0 </td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Italics">Adverse Reactions in OCD Placebo Controlled Studies Which are Markedly Different (defined as at least a two-fold difference) in Rate from the Pooled Reaction Rates in OCD and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></span></span><span class="Bold"><span class="Italics">Placebo Controlled Studies:</span></span> The reactions in OCD studies with a two-fold decrease in rate compared to reaction rates in OCD and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> studies were <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span> and <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">amblyopia</span> (mostly <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>). Additionally, there was an approximate 25% decrease in <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. </p>
<p>The reactions in OCD studies with a two-fold increase in rate compared to reaction rates in OCD and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> studies were: <span class="Italics"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">abnormal ejaculation</span> (mostly delayed ejaculation),</span><span class="Italics"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">anorgasmia</span> (in males), <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">libido decreased</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>,</span><span class="Italics"><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>/twitch, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>,</span> and <span class="Italics"><span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span></span>. These reactions are listed in order of decreasing rates in the OCD trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6f22926a-e32f-4637-a6d1-73309af745f5"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Other Adverse Reactions in OCD Pediatric Population</h2>
<p class="First">In pediatric patients (N = 57) treated with fluvoxamine maleate tablets, the overall profile of adverse reactions was generally similar to that seen in adult studies, as shown in <span class="Bold">Table 2</span>. However, the following adverse reactions, not appearing in <span class="Bold">Table 2</span>, were reported in two or more of the pediatric patients and were more frequent with fluvoxamine maleate tablets than with placebo: <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> increase, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic reaction</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ee2fb6c3-da3c-4443-b996-cea281aa9db5"></a><a name="section-6.4"></a><p></p>
<h2>6.4 Male and Female <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">Sexual Dysfunction</span> With SSRIs</h2>
<p class="First">Although changes in sexual desire, sexual performance and sexual satisfaction often occur as manifestations of a psychiatric disorder and with aging, they may also be a consequence of pharmacologic treatment. In particular, some evidence suggests that selective serotonin reuptake inhibitors (SSRIs), can cause such untoward sexual experiences. </p>
<p>Reliable estimates of the incidence and severity of untoward experiences involving sexual desire, performance and satisfaction are difficult to obtain, however, in part because patients and physicians may be reluctant to discuss them. Accordingly, estimates of the incidence of untoward sexual experience and performance cited in product labeling are likely to underestimate their actual incidence. </p>
<p><span class="Bold">Table 3</span> displays the incidence of sexual side effects reported by at least 2% of patients taking fluvoxamine maleate tablets in placebo-controlled trials in <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and OCD.</p>
<table border="1">
<caption><span>Table 3: PERCENTAGE OF PATIENTS REPORTING SEXUAL ADVERSE REACTIONS IN ADULT PLACEBO-CONTROLLED TRIALS IN OCD AND <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span> </span></caption>
<col width="35.9%">
<col width="36.6%">
<col width="27.5%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>Based on the number of male patients.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">Â  Â  </td>
<td class="Botrule Rrule" align="center" valign="top">Â <span class="Bold">Fluvoxamine Maleate Tablets</span><span class="Bold">N = 892</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <span class="Bold"> Placebo</span><span class="Bold">N = 778</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">Abnormal Ejaculation</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â  8% </td>
<td class="Botrule Rrule" align="center" valign="top">Â  1% </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span><a href="#footnote-7" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â  2% </td>
<td class="Botrule Rrule" align="center" valign="top">Â  1% </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  Decreased Libido </td>
<td class="Botrule Rrule" align="center" valign="top">Â  2% </td>
<td class="Botrule Rrule" align="center" valign="top">Â  1% </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">Anorgasmia</span> </td>
<td class="Rrule" align="center" valign="top">Â  2% </td>
<td class="Botrule Rrule" align="center" valign="top">Â  0% </td>
</tr>
</tbody>
</table>
<p>There are no adequate and well-controlled studies examining <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> with fluvoxamine treatment. </p>
<p>Fluvoxamine treatment has been associated with several cases of <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>. In those cases with a known outcome, patients recovered without sequelae and upon discontinuation of fluvoxamine. </p>
<p>While it is difficult to know the precise risk of <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> associated with the use of SSRIs, physicians should routinely inquire about such possible side effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_49e90d09-2f15-4887-a926-b4728df2fd0a"></a><a name="section-6.5"></a><p></p>
<h2>6.5 Vital Sign Changes</h2>
<p class="First">Comparisons of fluvoxamine maleate and placebo groups in separate pools of short-term OCD and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> trials on (1) median change from baseline on various vital signs variables and on (2) incidence of patients meeting criteria for potentially important changes from baseline on various vital signs variables revealed no important differences between fluvoxamine maleate and placebo. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9bb1eb49-ea24-4735-9778-86850f4bff61"></a><a name="section-6.6"></a><p></p>
<h2>6.6 Laboratory Changes</h2>
<p class="First">Comparisons of fluvoxamine maleate and placebo groups in separate pools of short-term OCD and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> trials on (1) median change from baseline on various serum chemistry, hematology, and urinalysis variables and on (2) incidence of patients meeting criteria for potentially important changes from baseline on various serum chemistry, hematology, and urinalysis variables revealed no important differences between fluvoxamine maleate and placebo. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_07bd89e6-4fec-4666-b024-3ef6fcf715de"></a><a name="section-6.7"></a><p></p>
<h2>6.7 ECG Changes</h2>
<p class="First">Comparisons of fluvoxamine maleate and placebo groups in separate pools of short-term OCD and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> trials on (1) mean change from baseline on various ECG variables and on (2) incidence of patients meeting criteria for potentially important changes from baseline on various ECG variables revealed no important differences between fluvoxamine maleate and placebo. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_18b97423-ad24-4af0-948a-2fa23ba169ff"></a><a name="section-6.8"></a><p></p>
<h2>6.8 Other Reactions Observed During the Premarketing Evaluation of Fluvoxamine Maleate Tablets</h2>
<p class="First">During premarketing clinical trials conducted in North America and Europe, multiple doses of fluvoxamine maleate were administered for a combined total of 2737 patient exposures in patients suffering OCD or Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>. Untoward reactions associated with this exposure were recorded by clinical investigators using descriptive terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse reactions without first grouping similar types of untoward reactions into a limited (i.e., reduced) number of standard reaction categories. </p>
<p>In the tabulations which follow, a standard COSTART-based Dictionary terminology has been used to classify reported adverse reactions. If the COSTART term for a reaction was so general as to be uninformative, it was replaced with a more informative term. The frequencies presented, therefore, represent the proportion of the 2737 patient exposures to multiple doses of fluvoxamine maleate who experienced a reaction of the type cited on at least one occasion while receiving fluvoxamine maleate. All reported reactions are included in the list below, with the following exceptions: 1) those reactions already listed in <span class="Bold">Table 2</span>, which tabulates incidence rates of common adverse experiences in placebo-controlled OCD and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> clinical trials, are excluded; 2) those reactions for which a drug cause was not considered likely are omitted; 3) reactions for which the COSTART term was too vague to be clinically meaningful and could not be replaced with a more informative term; and 4) reactions which were reported in only one patient and judged to not be potentially serious are not included. It is important to emphasize that, although the reactions reported did occur during treatment with fluvoxamine maleate, a causal relationship to fluvoxamine maleate has not been established. </p>
<p>Reactions are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: frequent adverse reactions are defined as those occurring on one or more occasions in at least 1/100 patients; infrequent adverse reactions are those occurring between 1/100 and 1/1000 patients; and rare adverse reactions are those occurring in less than 1/1000 patients. </p>
<p><span class="Bold">Body as a Whole</span> â€“ <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span> and <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span>. </p>
<p><span class="Bold">Cardiovascular System</span> â€“ <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>. </p>
<p><span class="Bold">Digestive System</span> â€“ <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span> and <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>; <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>. </p>
<p><span class="Bold">Hemic and Lymphatic Systems</span> â€“ <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>; <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>. </p>
<p><span class="Bold">Metabolic and Nutritional Systems</span> â€“ <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. </p>
<p><span class="Bold">Nervous System</span> â€“ <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic reaction</span>, and <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal syndrome</span>, and <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>; <span class="Italics">Rare:</span> withdrawal syndrome. </p>
<p><span class="Bold">Respiratory System</span> â€“ <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span> and <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngismus</span>. </p>
<p><span class="Bold">Skin</span> â€“ <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>. </p>
<p><span class="Bold">Urogenital System</span><span class="Sup">*</span> â€“ <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">menorrhagia</span>, and <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal hemorrhage</span>; <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="439871" conceptname="Hemospermia">hematospermia</span>. </p>
<p><span class="Bold"><span class="Sup">*</span></span> Based on the number of males or females, as appropriate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2cfae073-8acf-410b-a79f-02e7a96b3eeb"></a><a name="section-6.9"></a><p></p>
<h2>6.9 Postmarketing Reports</h2>
<p class="First">Voluntary reports of adverse reactions in patients taking fluvoxamine maleate tablets that have been received since market introduction and are of unknown causal relationship to fluvoxamine maleate tablets use include: <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous eruption</span>, Henoch-Schoenlein <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, and <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> (including <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>). </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_d5f9d0a8-3d7c-432c-9595-f1c960887f7a"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_37cf4536-db24-4ba5-b1bc-e86ee96f3708"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Potential Interactions With Drugs That Inhibit or are Metabolized by Cytochrome P450 Isoenzymes</h2>
<p class="First">Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds. The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> studies conducted in healthy volunteers, but some preliminary <span class="Italics">in vitro</span> data are also available. Based on a finding of substantial interactions of fluvoxamine with certain of these drugs (see later parts of this section and also <span class="Bold">WARNINGS AND PRECAUTIONS</span> [<a href="#LINK_d9ee8f37-7598-4021-bd6b-90ccfe7af386">5</a>]) and limited <span class="Italics">in vitro</span> data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole). </p>
<p><span class="Italics">In vitro</span> data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6. </p>
<p>Approximately 7% of the normal population has a genetic code that leads to reduced levels of activity of CYP2D6. Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants. While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an <span class="Italics">in vivo</span> study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean C<span class="Sub">max</span>, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group. This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6. Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine). </p>
<p>The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied. </p>
<p>A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin. If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached (see <span class="Bold">CONTRAINDICATIONS</span> [<a href="#LINK_e4b468a0-af7f-43bc-a743-e16338cff18a">4</a>] and <span class="Bold">WARNINGS AND PRECAUTIONS</span> [<a href="#LINK_d9ee8f37-7598-4021-bd6b-90ccfe7af386">5</a>]). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7be4d217-5c07-4193-a918-de970adc431d"></a><a name="section-7.2"></a><p></p>
<h2>7.2 CNS Active Drugs</h2>
<p class="First"><span class="Bold"><span class="Italics">Antipsychotics:</span></span> See <span class="Bold">WARNINGS AND PRECAUTIONS</span> (<a href="#LINK_63c287fc-8a3a-4736-9d90-e2b4c0573137">5.3</a>). </p>
<p><span class="Bold"><span class="Italics">Benzodiazepines:</span></span> See <span class="Bold">WARNINGS AND PRECAUTIONS</span> (<a href="#LINK_a38970d6-c303-4089-bf6e-49f0f281a2bb">5.8</a>). </p>
<p><span class="Bold"><span class="Italics">Alprazolam:</span></span> See <span class="Bold">WARNINGS AND PRECAUTIONS</span> (<a href="#LINK_a38970d6-c303-4089-bf6e-49f0f281a2bb">5.8</a>). </p>
<p><span class="Bold"><span class="Italics">Diazepam:</span></span> See <span class="Bold">WARNINGS AND PRECAUTIONS</span> (<a href="#LINK_a38970d6-c303-4089-bf6e-49f0f281a2bb">5.8</a>). </p>
<p><span class="Bold"><span class="Italics">Lorazepam:</span></span> A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span>. On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone. </p>
<p><span class="Bold"><span class="Italics">Alcohol:</span></span> Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other. As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.</p>
<p><span class="Bold"><span class="Italics">Carbamazepine:</span></span> Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine. </p>
<p><span class="Bold"><span class="Italics">Clozapine:</span></span> See <span class="Bold">WARNINGS AND PRECAUTIONS</span> (<a href="#LINK_a38970d6-c303-4089-bf6e-49f0f281a2bb">5.8</a>).</p>
<p><span class="Bold"><span class="Italics">Lithium:</span></span> As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> have been reported with the coadministration of fluvoxamine maleate and lithium. </p>
<p><span class="Bold"><span class="Italics">Methadone:</span></span> See <span class="Bold">WARNINGS AND PRECAUTIONS</span> (<a href="#LINK_a38970d6-c303-4089-bf6e-49f0f281a2bb">5.8</a>). </p>
<p><span class="Bold"><span class="Italics">Monoamine Oxidase Inhibitors:</span></span> See <span class="Bold">CONTRAINDICATIONS</span> (<a href="#LINK_e4b468a0-af7f-43bc-a743-e16338cff18a">4</a>) and <span class="Bold">WARNINGS AND PRECAUTIONS</span> (<a href="#LINK_d8a1ba75-9d20-4e7d-9f09-daf8f7da60d1">5.2</a>). </p>
<p><span class="Bold"><span class="Italics">Pimozide:</span></span> See <span class="Bold">CONTRAINDICATIONS</span> (<a href="#LINK_e4b468a0-af7f-43bc-a743-e16338cff18a">4</a>) and <span class="Bold">WARNINGS AND PRECAUTIONS</span> (<a href="#LINK_065606d4-0c80-4551-9a56-12e3cc49eaf4">5.6</a>). </p>
<p><span class="Bold"><span class="Italics">Ramelteon:</span></span> See <span class="Bold">WARNINGS AND PRECAUTIONS</span> (<a href="#LINK_a38970d6-c303-4089-bf6e-49f0f281a2bb">5.8</a>). </p>
<p><span class="Bold"><span class="Italics">Serotonergic Drugs:</span></span> See <span class="Bold">WARNINGS AND PRECAUTIONS</span> (<a href="#LINK_63c287fc-8a3a-4736-9d90-e2b4c0573137">5.3</a>).</p>
<p><span class="Bold"><span class="Italics">Tacrine:</span></span> In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine C<span class="Sub">max</span> and AUC, respectively, compared to the administration of tacrine alone. Five subjects experienced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following coadministration, consistent with the cholinergic effects of tacrine. </p>
<p><span class="Bold"><span class="Italics">Thioridazine:</span></span> See <span class="Bold">CONTRAINDICATIONS</span> (<a href="#LINK_e4b468a0-af7f-43bc-a743-e16338cff18a">4</a>) and <span class="Bold">WARNINGS AND PRECAUTIONS</span> (<a href="#LINK_87de6cd3-0b15-429c-9ef1-4f29e337db05">5.4</a>). </p>
<p><span class="Bold"><span class="Italics">Tizanidine:</span></span> See <span class="Bold">CONTRAINDICATIONS</span> (<a href="#LINK_e4b468a0-af7f-43bc-a743-e16338cff18a">4</a>) and <span class="Bold">WARNINGS AND PRECAUTIONS</span> (<a href="#LINK_8581f9ea-ef79-4529-8aa2-84d6410677e9">5.5</a>). </p>
<p><span class="Bold"><span class="Italics">Tricyclic Antidepressants (TCAs):</span></span> Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine. Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced. </p>
<p><span class="Bold"><span class="Italics">Triptans:</span></span> There have been rare postmarketing reports of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with use of an SSRI and a triptan. If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see <span class="Bold">WARNINGS AND PRECAUTIONS</span> [<a href="#LINK_63c287fc-8a3a-4736-9d90-e2b4c0573137">5.3</a>]). </p>
<p><span class="Bold">Sumatriptan</span> - There have been rare postmarketing reports describing patients with <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, and <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span> following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan. If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised. </p>
<p><span class="Bold"><span class="Italics">Tryptophan:</span></span> Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution. Severe <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> has been reported with the coadministration of fluvoxamine maleate and tryptophan (see <span class="Bold">WARNINGS AND PRECAUTIONS</span> [<a href="#LINK_63c287fc-8a3a-4736-9d90-e2b4c0573137">5.3</a>]). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5c5c5d90-be3a-426e-85d4-ad9263ead085"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Other Drugs</h2>
<p class="First"><span class="Bold"><span class="Italics">Alosetron:</span></span> See <span class="Bold">CONTRAINDICATIONS</span> [<a href="#LINK_e4b468a0-af7f-43bc-a743-e16338cff18a">4</a>], <span class="Bold">WARNINGS AND PRECAUTIONS</span> [<a href="#LINK_51997691-e6f7-4af2-86bc-875010a13dc6">5.7</a>], and LotronexÂ® (alosetron) package insert. </p>
<p><span class="Bold"><span class="Italics">Digoxin: </span></span>Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin. </p>
<p><span class="Bold"><span class="Italics">Diltiazem: </span></span><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> has been reported with the coadministration of fluvoxamine maleate and diltiazem. </p>
<p><span class="Bold"><span class="Italics">Mexiletine:</span></span> See <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_a38970d6-c303-4089-bf6e-49f0f281a2bb">5.8</a>)</span>. </p>
<p><span class="Bold"><span class="Italics">Propranolol and Other Beta-Blockers: </span></span>Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure. </p>
<p>One case of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and a second case of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> have been reported with the coadministration of fluvoxamine maleate and metoprolol. </p>
<p>If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended. No dosage adjustment is required for fluvoxamine maleate tablets.</p>
<p>Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol. Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion. </p>
<p><span class="Bold"><span class="Italics">Theophylline: </span></span>See <span class="Bold">WARNINGS AND PRECAUTIONS (<a href="#LINK_a38970d6-c303-4089-bf6e-49f0f281a2bb">5.8</a>)</span>. </p>
<p><span class="Bold"><span class="Italics">Warfarin and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.):</span></span> See <span class="Bold">WARNINGS AND PRECAUTIONS </span>[<a href="#LINK_a38970d6-c303-4089-bf6e-49f0f281a2bb">5.8 </a>and <a href="#LINK_7373ae12-0e72-4d83-b8d3-d0c44ebfa0c7">5.10</a>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_edf6e6d5-6668-42ea-bfc0-256767c997ee"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Effects of Smoking on Fluvoxamine Metabolism</h2>
<p class="First">Smokers had a 25% increase in the metabolism of fluvoxamine compared to <span class="product-label-link" type="condition" conceptid="4222303" conceptname="Non-smoker">nonsmokers</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_73de90a8-7bf0-441b-80b8-4a91e057eefb"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Electroconvulsive Therapy (ECT)</h2>
<p class="First">There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate. </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_2fa0fc6b-0d3c-4775-a75d-531ab05982f9"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_4d42ec68-2e52-4496-9a7c-4127291a917b"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_bcc60dd5-b912-4b80-a908-b376c6783e5a"></a><a name="section-8.1.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<p class="First"><span class="Bold"><span class="Italics">Pregnancy Category C:</span></span> When pregnant rats were given oral doses of fluvoxamine (60, 120, or 240 mg/kg) throughout the period of organogenesis, developmental toxicity in the form of increased embryofetal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and increased incidences of fetal eye abnormalities (folded retinas) was observed at doses of 120 mg/kg or greater. Decreased fetal body weight was seen at the high dose. The no effect dose for developmental toxicity in this study was 60 mg/kg (approximately 2 times the MRHD on a mg/m<span class="Sup">2</span> basis). </p>
<p>In a study in which pregnant rabbits were administered doses of up to 40 mg/kg (approximately 2 times the MRHD on a mg/m<span class="Sup">2</span> basis) during organogenesis, no adverse effects on embryofetal development were observed. </p>
<p>In other reproduction studies in which female rats were dosed orally during pregnancy and lactation (5, 20, 80, or 160 mg/kg), increased pup mortality at birth was seen at doses of 80 mg/kg or greater and decreases in pup body weight and survival were observed at all doses (low effect dose approximately 0.1 times the MRHD on a mg/m<span class="Sup">2</span> basis). </p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="LINK_78912e00-2a45-4444-8ce6-02598e058e56"></a><a name="section-8.1.2"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First">Neonates exposed to fluvoxamine maleate and other SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs) late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. These findings are based on postmarketing reports. Such complications can arise immediately upon delivery. Reported clinical findings have included <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, temperature instability, feeding difficulty, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">jitteriness</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> and constant <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>. These features are consistent with either a direct toxic effect of SSRIs or SNRIs or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> (see <span class="Bold">WARNINGS AND PRECAUTIONS</span> [<a href="#LINK_63c287fc-8a3a-4736-9d90-e2b4c0573137">5.3</a>]). </p>
<p>Infants exposed to SSRIs in late pregnancy may have an increased risk for persistent <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> of the newborn (PPHN). PPHN is associated with substantial neonatal morbidity and mortality. In a case-control study of 377 women whose infants were born with PPHN and 836 women whose infants were born healthy, the risk for developing PPHN was approximately six-fold higher for infants exposed to SSRIs after the 20<span class="Sup">th</span> week of gestation compared to infants who had not been exposed to antidepressants during pregnancy. PPHN occurs in 1 to 2 per 1000 live births in the general population. </p>
<p>When treating a pregnant woman with fluvoxamine maleate during the third trimester, the physician should carefully consider both the potential risks and benefits of treatment (see <span class="Bold">DOSAGE AND ADMINISTRATION</span> [<a href="#LINK_0a97c798-48e8-4c97-b2c8-f71fff2315a3">2.4</a>]). Physicians should note that in a prospective longitudinal study of 201 women with a history of <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">major depression</span> who were euthymic at the beginning of pregnancy, women who discontinued antidepressant medication during pregnancy were more likely to experience a relapse of <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">major depression</span> than women who continued antidepressant medication. </p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="LINK_27f13dc2-c542-4a32-98dd-508ed49ec31d"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">The effect of fluvoxamine on labor and delivery in humans is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_0c47abe1-d82e-402d-a20d-18d400e5b133"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">As for many other drugs, fluvoxamine is secreted in human breast milk. The decision of whether to discontinue nursing or to discontinue the drug should take into account the potential for serious adverse effects from exposure to fluvoxamine in the nursing infant as well as the potential benefits of fluvoxamine maleate tablet therapy to the mother. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_4dd006ec-bb5f-47b7-aeb3-152dec0fa4fd"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The efficacy of fluvoxamine maleate for the treatment of <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">obsessive compulsive disorder</span> was demonstrated in a 10 week multicenter placebo controlled study with 120 outpatients ages 8 to 17. In addition, 99 of these outpatients continued open-label fluvoxamine maleate treatment for up to another one to three years, equivalent to 94 patient years. The adverse event profile observed in that study was generally similar to that observed in adult studies with fluvoxamine (see <span class="Bold">ADVERSE REACTIONS</span> [<a href="#LINK_6f22926a-e32f-4637-a6d1-73309af745f5">6.3</a>] and <span class="Bold">DOSAGE AND ADMINISTRATION</span> [<a href="#LINK_6e621988-2376-4efa-b3b3-d91508c2b3c5">2.2</a>]). </p>
<p><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span> and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> have been observed in association with the use of fluvoxamine as well as other SSRIs. Consequently, regular monitoring of weight and growth is recommended if treatment of a child with an SSRI is to be continued long term. </p>
<p>The risks, if any, that may be associated with fluvoxamineâ€™s extended use in children and adolescents with OCD have not been systematically assessed. The prescriber should be mindful that the evidence relied upon to conclude that fluvoxamine is safe for use in children and adolescents derives from relatively short term clinical studies and from extrapolation of experience gained with adult patients. In particular, there are no studies that directly evaluate the effects of long term fluvoxamine use on the growth, cognitive behavioral development, and maturation of children and adolescents. Although there is no affirmative finding to suggest that fluvoxamine possesses a capacity to adversely affect growth, development or maturation, the absence of such findings is not compelling evidence of the absence of the potential of fluvoxamine to have adverse effects in chronic use (see <span class="Bold">WARNINGS AND PRECAUTIONS</span>, <span class="Bold">Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</span> [<a href="#LINK_6e4d7b0d-4f91-48a9-a17c-a75415c80d10">5.1</a>]). </p>
<p>Safety and effectiveness in the pediatric population other than pediatric patients with OCD have not been established (see BOXED WARNING and <span class="Bold">WARNINGS AND PRECAUTIONS</span>, <span class="Bold">Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</span> [<a href="#LINK_6e4d7b0d-4f91-48a9-a17c-a75415c80d10">5.1</a>]). Anyone considering the use of fluvoxamine maleate tablets in a child or adolescent must balance the potential risks with the clinical need.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_2e4b9598-daae-4158-97d1-b5d0403803f7"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Approximately 230 patients participating in controlled premarketing studies with fluvoxamine maleate tablets were 65 years of age or over. No overall differences in safety were observed between these patients and younger patients. Other reported clinical experience has not identified differences in response between the elderly and younger patients. However, SSRIs and SNRIs, including fluvoxamine maleate tablets, have been associated with several cases of clinically significant <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> in elderly patients, who may be at greater risk for this adverse event (see <span class="Bold">WARNINGS AND PRECAUTIONS</span> [<a href="#LINK_4a5cf584-a2e0-4fd9-9e2e-c7434d11fd68">5.13</a>]). Furthermore, the clearance of fluvoxamine is decreased by about 50% in elderly compared to younger patients (see <span class="Bold">CLINICAL</span><span class="Bold">PHARMACOLOGY</span>, <span class="Bold">Elderly</span> [<a href="#LINK_cd4f2edb-8d42-43c1-8097-b3f97a4634f7">12.3</a>]), and greater sensitivity of some older individuals also cannot be ruled out. Consequently, a lower starting dose should be considered in elderly patients and fluvoxamine maleate tablets should be slowly titrated during initiation of therapy. </p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="LINK_61ad3fc4-55de-423b-b632-35bda371468f"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="LINK_7b6a1751-606c-44a1-b8af-e9d5f8b35801"></a><a name="section-9.1"></a><p></p>
<h2>9.1 Controlled Substance</h2>
<p class="First">Fluvoxamine maleate tablets are not a controlled substance. </p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="LINK_5af97585-4c4a-4425-8439-a7352093ae54"></a><a name="section-9.2"></a><p></p>
<h2>9.2 Abuse</h2>
<p class="First">The potential for abuse, tolerance and physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> with fluvoxamine maleate has been studied in a nonhuman primate model. No evidence of dependency phenomena was found. The discontinuation effects of fluvoxamine maleate tablets were not systematically evaluated in controlled clinical trials. Fluvoxamine maleate tablets were not systematically studied in clinical trials for potential for abuse, but there was no indication of drug-seeking behavior in clinical trials. It should be noted, however, that patients at risk for drug dependency were systematically excluded from investigational studies of fluvoxamine maleate. Generally, it is not possible to predict on the basis of preclinical or premarketing clinical experience the extent to which a CNS active drug will be misused, diverted, and/or abused once marketed. Consequently, physicians should carefully evaluate patients for a history of drug abuse and follow such patients closely, observing them for signs of fluvoxamine maleate misuse or abuse (i.e., development of tolerance, incrementation of dose, drug-seeking behavior). </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_c5d16d03-f5f3-43f5-8104-54dcccd52a37"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6e40a8fc-4418-48b5-9ed2-21291b8dde7d"></a><a name="section-10.1"></a><p></p>
<h2>10.1 Human Experience</h2>
<p class="First">Worldwide exposure to fluvoxamine includes over 45,000 patients treated in clinical trials and an estimated exposure of 50,000,000 patients treated during worldwide marketing experience (end of 2005). Of the 539 cases of deliberate or accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> involving fluvoxamine reported from this population, there were 55 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>. Of these, 9 were in patients thought to be taking fluvoxamine alone and the remaining 46 were in patients taking fluvoxamine along with other drugs. Among non-fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> cases, 404 patients recovered completely. Five patients experienced adverse sequelae of overdosage, to include persistent <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">unsteady gait</span>, <span class="product-label-link" type="condition" conceptid="377845" conceptname="Anoxic encephalopathy">hypoxic encephalopathy</span>, kidney complications (from <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> associated with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>), bowel <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> requiring a hemicolectomy, and vegetative state. In 13 patients, the outcome was provided as abating at the time of reporting. In the remaining 62 patients, the outcome was unknown. The largest known ingestion of fluvoxamine involved 12,000 mg (equivalent to 2 to 3 months' dosage). The patient fully recovered. However, ingestions as low as 1,400 mg have been associated with lethal outcome, indicating considerable prognostic variability.</p>
<p>Commonly (â‰¥ 5%) observed adverse events associated with fluvoxamine maleate <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> include gastrointestinal complaints (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>), <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, respiratory difficulties, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. Other notable signs and symptoms seen with fluvoxamine maleate <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (single or multiple drugs) include <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, ECG abnormalities (such as <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">heart arrest</span>, QT interval prolongation, <span class="product-label-link" type="condition" conceptid="314379" conceptname="First degree atrioventricular block">first degree atrioventricular block</span>, <span class="product-label-link" type="condition" conceptid="313791" conceptname="Bundle branch block">bundle branch block</span>, and <span class="product-label-link" type="condition" conceptid="4038688" conceptname="AV junctional rhythm">junctional rhythm</span>), <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, liver function disturbances, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, and <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">increased reflexes</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7aa473f4-12ae-4a5b-a2dc-a7a3a296fe2f"></a><a name="section-10.2"></a><p></p>
<h2>10.2 Management of Overdosage</h2>
<p class="First">Treatment should consist of those general measures employed in the management of overdosage with any antidepressant. </p>
<p>Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion, or in symptomatic patients. </p>
<p>Activated charcoal should be administered. Due to the large volume of distribution of this drug, forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, dialysis, hemoperfusion and exchange transfusion are unlikely to be of benefit. No specific antidotes for fluvoxamine are known. </p>
<p>A specific caution involves patients taking, or recently having taken, fluvoxamine who might ingest excessive quantities of a tricyclic antidepressant. In such a case, accumulation of the parent tricyclic and/or an active metabolite may increase the possibility of clinically significant sequelae and extend the time needed for close medical observation (see <span class="Bold">DRUG INTERACTIONS</span> [<a href="#LINK_7be4d217-5c07-4193-a918-de970adc431d">7.2</a>]). </p>
<p>In managing overdosage, consider the possibility of multiple drug involvement. The physician should consider contacting a poison control center for additional information on the treatment of any <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Telephone numbers for certified poison control centers are listed in the <span class="Italics">Physiciansâ€™ Desk Reference</span> (PDR). </p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_f2af9222-c1e4-4403-87ef-9ad210be62d2"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Fluvoxamine maleate is a selective serotonin (5-HT) reuptake inhibitor (SSRI) belonging to the chemical series, the 2-aminoethyl oxime ethers of aralkylketones. </p>
<p>It is chemically designated as 5-methoxy-4â€²-(trifluoromethyl)valerophenone-(<span class="Italics">E</span>)-<span class="Italics">O</span>-(2-aminoethyl)oxime maleate (1:1).</p>
<p>The structural formula is:</p>
<div class="Figure"><img alt="Structural formula for fluvoxamine maleate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=727a5eb4-ac82-444d-8381-44c34ee3b895&amp;name=fluvoxamine-maleate-1.jpg"></div>
<p>C<span class="Sub">15</span>H<span class="Sub">21</span>O<span class="Sub">2</span>N<span class="Sub">2</span>F<span class="Sub">3</span>â€¢C<span class="Sub">4</span>H<span class="Sub">4</span>O<span class="Sub">4</span>      M.W. 434.4</p>
<p>Fluvoxamine maleate is a white or off-white, odorless, crystalline powder which is sparingly soluble in water, freely soluble in ethanol and chloroform and practically insoluble in diethyl ether.</p>
<p>Fluvoxamine maleate tablets USP are available in 25 mg, 50 mg and 100 mg strengths for oral administration. In addition to the active ingredient, fluvoxamine maleate, each tablet contains the following inactive ingredients: colloidal silicon dioxide, hydroxypropyl cellulose, hypromellose, mannitol, mannitol granulate, polyethylene glycol 400, polysorbate 80, pregelatinized starch, sodium stearyl fumarate, and titanium dioxide. Additionally each 50 mg and 100 mg tablet contains: iron oxide black, iron oxide red, and iron oxide yellow.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_23b2c697-4654-4616-99ab-aca2681562cd"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_8cd3c6a6-94ea-441b-ae67-36f1cac53989"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The mechanism of action of fluvoxamine maleate in <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">obsessive compulsive disorder</span> is presumed to be linked to its specific serotonin reuptake inhibition in brain neurons. Fluvoxamine has been shown to be a potent inhibitor of the serotonin reuptake transporter in preclinical studies, both <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span>. </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="LINK_d065a667-9a0c-4d67-92ef-53442bda731e"></a><a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">In <span class="Italics">in vitro</span> studies, fluvoxamine maleate had no significant affinity for histaminergic, alpha or beta adrenergic, muscarinic, or dopaminergic receptors. Antagonism of some of these receptors is thought to be associated with various sedative, cardiovascular, anticholinergic, and extrapyramidal effects of some psychotropic drugs. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_cd4f2edb-8d42-43c1-8097-b3f97a4634f7"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Bold"><span class="Italics">Absorption: </span></span> The absolute bioavailability of fluvoxamine maleate is 53%. Oral bioavailability is not significantly affected by food. </p>
<p>In a dose proportionality study involving fluvoxamine maleate at 100, 200 and 300 mg/day for 10 consecutive days in 30 normal volunteers, steady state was achieved after about a week of dosing. Maximum plasma concentrations at steady state occurred within 3 to 8 hours of dosing and reached concentrations averaging 88, 283 and 546 ng/mL, respectively. Thus, fluvoxamine had nonlinear pharmacokinetics over this dose range, i.e., higher doses of fluvoxamine maleate produced disproportionately higher concentrations than predicted from the lower dose. </p>
<p><span class="Bold"><span class="Italics">Distribution:</span></span> The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution. </p>
<p>Approximately 80% of fluvoxamine is bound to plasma protein, mostly albumin, over a concentration range of 20 to 2000 ng/mL. </p>
<p><span class="Bold"><span class="Italics">Metabolism: </span></span>Fluvoxamine maleate is extensively metabolized by the liver; the main metabolic routes are oxidative demethylation and deamination. Nine metabolites were identified following a 5 mg radiolabelled dose of fluvoxamine maleate, constituting approximately 85% of the urinary excretion products of fluvoxamine. The main human metabolite was fluvoxamine acid which, together with its N-acetylated analog, accounted for about 60% of the urinary excretion products. A third metabolite, fluvoxethanol, formed by oxidative deamination, accounted for about 10%. Fluvoxamine acid and fluvoxethanol were tested in an <span class="Italics">in vitro</span> assay of serotonin and norepinephrine reuptake inhibition in rats; they were inactive except for a weak effect of the former metabolite on inhibition of serotonin uptake (1 to 2 orders of magnitude less potent than the parent compound). Approximately 2% of fluvoxamine was excreted in urine unchanged (see <span class="Bold">DRUG INTERACTIONS </span>[<a href="#LINK_d5f9d0a8-3d7c-432c-9595-f1c960887f7a">7</a>]). </p>
<p><span class="Bold"><span class="Italics">Elimination: </span></span>Following a <span class="Sup">14</span>C-labelled oral dose of fluvoxamine maleate (5 mg), an average of 94% of drug-related products was recovered in the urine within 71 hours. </p>
<p>The mean plasma half-life of fluvoxamine at steady state after multiple oral doses of 100 mg/day in healthy, young volunteers was 15.6 hours. </p>
<p><span class="Bold"><span class="Italics">Elderly Subjects:</span></span> In a study of fluvoxamine maleate tablets at 50 and 100 mg comparing elderly (ages 66 to 73) and young subjects (ages 19 to 35), mean maximum plasma concentrations in the elderly were 40% higher. The multiple dose elimination half-life of fluvoxamine was 17.4 and 25.9 hours in the elderly compared to 13.6 and 15.6 hours in the young subjects at steady state for 50 and 100 mg doses, respectively. In elderly patients, the clearance of fluvoxamine was reduced by about 50% and, therefore, fluvoxamine maleate tablets should be slowly titrated during initiation of therapy (see <span class="Bold">DOSAGE AND ADMINISTRATION </span>[<a href="#LINK_6a36a31f-567c-4cf8-8542-564e2947e08f">2.3</a>]). </p>
<p><span class="Bold"><span class="Italics">Pediatric Subjects:</span></span> The multiple-dose pharmacokinetics of fluvoxamine were determined in male and female children (ages 6 to 11) and adolescents (ages 12 to 17). Steady-state plasma fluvoxamine concentrations were 2 to 3 fold higher in children than in adolescents. AUC and C<span class="Sub">max</span> in children were 1.5 to 2.7 fold higher than that in adolescents (see <span class="Bold">Table 4</span>). As in adults, both children and adolescents exhibited nonlinear multiple-dose pharmacokinetics. Female children showed significantly higher AUC (0 to 12) and C<span class="Sub">max</span> compared to male children and, therefore, lower doses of fluvoxamine maleate tablets may produce therapeutic benefit (see <span class="Bold">Table 5</span>). No gender differences were observed in adolescents. Steady-state plasma fluvoxamine concentrations were similar in adults and adolescents at a dose of 300 mg/day, indicating that fluvoxamine exposure was similar in these two populations (see <span class="Bold">Table 4</span>). Dose adjustment in adolescents (up to the adult maximum dose of 300 mg) may be indicated to achieve therapeutic benefit (see <span class="Bold">DOSAGE AND ADMINISTRATION </span>[<a href="#LINK_6e621988-2376-4efa-b3b3-d91508c2b3c5">2.2</a>]).</p>
<table border="1">
<caption><span>Table 4: COMPARISON OF MEAN (SD) FLUVOXAMINE PHARMACOKINETIC PARAMETERS BETWEEN CHILDREN, ADOLESCENTS, AND ADULTS </span></caption>
<col width="31.0%">
<col width="21.0%">
<col width="17.1%">
<col width="16.3%">
<col width="14.5%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2">Â <span class="Bold">Pharmacokinetic Parameter (body weight corrected)</span><span class="Bold">Â </span>
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">Â <span class="Bold">Dose = 200 mg/day </span><span class="Bold">(100 mg b.i.d.)</span>
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">Â <span class="Bold">Dose = 300 mg/day (150 mg b.i.d.) </span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">Â <span class="Bold">Children </span><span class="Bold">(N = 10)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <span class="Bold">Adolescent </span><span class="Bold">(N = 17)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <span class="Bold">Adolescent </span><span class="Bold">(N = 13)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <span class="Bold">Adult (N = 16)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">Â  AUC<span class="Sub">0-12</span> (ngâ€¢h/mL/kg) </td>
<td class="Botrule Rrule" align="center" valign="top">Â  155.1 (160.9) </td>
<td class="Botrule Rrule" align="center" valign="top">Â  43.9 (27.9) </td>
<td class="Botrule Rrule" align="center" valign="top">Â  69.6 (46.6) </td>
<td class="Botrule Rrule" align="center" valign="top">Â  59.4 (40.9) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">Â  C<span class="Sub">max</span> (ng/mL/kg) </td>
<td class="Botrule Rrule" align="center" valign="top">Â  14.8 (14.9) </td>
<td class="Botrule Rrule" align="center" valign="top">Â  4.2 (2.6) </td>
<td class="Botrule Rrule" align="center" valign="top">Â  6.7 (4.2) </td>
<td class="Botrule Rrule" align="center" valign="top">Â  5.7 (3.9) </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">Â  C<span class="Sub">min</span> (ng/mL/kg) </td>
<td class="Rrule" align="center" valign="top">Â  11.0 (11.9) </td>
<td class="Rrule" align="center" valign="top">Â  2.9 (2.0) </td>
<td class="Rrule" align="center" valign="top">Â  4.8 (3.8) </td>
<td class="Botrule Rrule" align="center" valign="top">Â  4.6 (3.2) </td>
</tr>
</tbody>
</table>
<table border="1">
<caption><span>Table 5: COMPARISON OF MEAN (SD) FLUVOXAMINE PHARMACOKINETIC PARAMETERS BETWEEN MALE AND FEMALE CHILDREN (6 TO 11 YEARS) </span></caption>
<col width="31.1%">
<col width="41.0%">
<col width="27.8%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top">Â <span class="Bold">Pharmacokinetic Parameter (body weight corrected)</span><span class="Bold">Â </span>
</td>
<td class="Botrule Rrule" align="center" colspan="2">Â <span class="Bold">Dose = 200 mg/day </span><span class="Bold">(100 mg b.i.d.)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">Â <span class="Bold">Male Children </span><span class="Bold">(N = 7)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <span class="Bold">Female Children </span><span class="Bold">(N = 3)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">Â  AUC<span class="Sub">0-12</span> (ngâ€¢h/mL/kg) </td>
<td class="Botrule Rrule" align="center" valign="top">Â  95.8 (83.9) </td>
<td class="Botrule Rrule" align="center" valign="top">Â  293.5 (233.0) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">Â  C<span class="Sub">max</span> (ng/mL/kg) </td>
<td class="Botrule Rrule" align="center" valign="top">Â  9.1 (7.6) </td>
<td class="Botrule Rrule" align="center" valign="top">Â  28.1 (21.1) </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">Â  C<span class="Sub">min</span> (ng/mL/kg) </td>
<td class="Rrule" align="center" valign="top">Â  6.6 (6.1) </td>
<td class="Botrule Rrule" align="center" valign="top">Â  21.2 (17.6) </td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Italics">Hepatic and <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span>:</span></span> A cross study comparison (healthy subjects versus patients with hepatic dysfunction) suggested a 30% decrease in fluvoxamine clearance in association with hepatic dysfunction. The mean minimum plasma concentrations in renally impaired patients (creatinine clearance of 5 to 45 mL/min) after 4 and 6 weeks of treatment (50 mg b.i.d., N = 13) were comparable to each other, suggesting no accumulation of fluvoxamine in these patients (see <span class="Bold">WARNINGS AND PRECAUTIONS</span>, <span class="Bold">Use in Patients with Concomitant Illness</span> [<a href="#LINK_deb471d3-574d-41d0-bead-50e4154b3fc4">5.14</a>]). </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_e14c8ee3-8f23-434d-9381-f0296589833c"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_93b351a0-c399-42e2-b2d3-3ded40af39b0"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Bold"><span class="Italics">Carcinogenesis:</span></span> There was no evidence of carcinogenicity in rats treated orally with fluvoxamine maleate for 30 months or hamsters treated orally with fluvoxamine maleate for 20 (females) or 26 (males) months. The daily doses in the high dose groups in these studies were increased over the course of the study from a minimum of 160 mg/kg to a maximum of 240 mg/kg in rats, and from a minimum of 135 mg/kg to a maximum of 240 mg/kg in hamsters. The maximum dose of 240 mg/kg is approximately 6 times the maximum human daily dose on a mg/m<span class="Sup">2</span> basis. </p>
<p><span class="Bold"><span class="Italics">Mutagenesis:</span></span> No evidence of genotoxic potential was observed in a mouse micronucleus test, an <span class="Italics">in vitro</span> chromosome aberration test, or the Ames microbial mutagen test with or without metabolic activation. </p>
<p><span class="Bold"><span class="Italics">Impairment of Fertility: </span></span>In a study in which male and female rats were administered fluvoxamine (60, 120, or 240 mg/kg) prior to and during mating and gestation, fertility was impaired at oral doses of 120 mg/kg or greater, as evidenced by increased latency to mating, decreased sperm count, decreased epididymal weight, and decreased pregnancy rate. In addition, the numbers of implantations and embryos were decreased at the highest dose. The no effect dose for fertility impairment was 60 mg/kg (approximately 2 times the maximum recommended human dose [MRHD] on a mg/m<span class="Sup">2</span> basis). </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_05592228-b2ad-4626-bea7-f8d300f3d62f"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2e0739ec-1915-482e-b2a5-fe30dc2826b3"></a><a name="section-14.1"></a><p></p>
<h2>14.1 Adult OCD Studies</h2>
<p class="First">The effectiveness of fluvoxamine maleate tablets for the treatment of <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">obsessive compulsive disorder</span> (OCD) was demonstrated in two 10 week multicenter, parallel group studies of adult outpatients. Patients in these trials were titrated to a total daily fluvoxamine maleate dose of 150 mg/day over the first two weeks of the trial, following which the dose was adjusted within a range of 100 to 300 mg/day (on a b.i.d. schedule), on the basis of response and tolerance. Patients in these studies had moderate to severe OCD (DSM-III-R), with mean baseline ratings on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), total score of 23. Patients receiving fluvoxamine maleate experienced mean reductions of approximately 4 to 5 units on the Y-BOCS total score, compared to a 2 unit reduction for placebo patients. </p>
<p><span class="Bold">Table 6</span> provides the outcome classification by treatment group on the Global Improvement item of the Clinical Global Impressions (CGI) scale for both studies combined. </p>
<table border="1">
<caption><span>Table 6: OUTCOME CLASSIFICATION (%) ON CGI-GLOBAL IMPROVEMENT ITEM FOR COMPLETERS IN POOL OF TWO ADULT OCD STUDIES </span></caption>
<col width="37.9%">
<col width="40.6%">
<col width="21.5%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">Â <span class="Bold">Outcome Classification</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <span class="Bold">Fluvoxamine (N = 120)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <span class="Bold">Placebo (N = 134)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  Very Much Improved </td>
<td class="Botrule Rrule" align="center" valign="top">Â  13% </td>
<td class="Botrule Rrule" align="center" valign="top">Â  2% </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  Much Improved </td>
<td class="Botrule Rrule" align="center" valign="top">Â  30% </td>
<td class="Botrule Rrule" align="center" valign="top">Â  10% </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  Minimally Improved </td>
<td class="Botrule Rrule" align="center" valign="top">Â  22% </td>
<td class="Botrule Rrule" align="center" valign="top">Â  32% </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  No Change </td>
<td class="Botrule Rrule" align="center" valign="top">Â  31% </td>
<td class="Botrule Rrule" align="center" valign="top">Â  51% </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">Â  Worse </td>
<td class="Rrule" align="center" valign="top">Â  4% </td>
<td class="Botrule Rrule" align="center" valign="top">Â  6% </td>
</tr>
</tbody>
</table>
<p>Exploratory analyses for age and gender effects on outcomes did not suggest any differential responsiveness on the basis of age or sex. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8a0ff469-7bf9-418e-9d14-ee56591487ef"></a><a name="section-14.2"></a><p></p>
<h2>14.3 Pediatric OCD Study</h2>
<p class="First">The effectiveness of fluvoxamine maleate tablets for the treatment of OCD was also demonstrated in a 10 week multicenter, parallel group study in a pediatric outpatient population (children and adolescents, ages 8 to 17). Patients in this study were titrated to a total daily fluvoxamine dose of approximately 100 mg/day over the first two weeks of the trial, following which the dose was adjusted within a range of 50 to 200 mg/day (on a b.i.d. schedule) on the basis of response and tolerance. All patients had moderate-to-severe OCD (DSM-III-R) with mean baseline ratings on the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) total score of 24. Patients receiving fluvoxamine maleate experienced mean reductions of approximately six units on the CY-BOCS total score, compared to a three-unit reduction for placebo patients. </p>
<p><span class="Bold">Table 7</span> provides the outcome classification by treatment group on the Global Improvement item of the Clinical Global Impression (CGI) scale for the pediatric study.</p>
<table border="1">
<caption><span>Table 7: OUTCOME CLASSIFICATION (%) ON CGI-GLOBAL IMPROVEMENT ITEM FOR COMPLETERS IN PEDIATRIC STUDY </span></caption>
<col width="35.1%">
<col width="37.1%">
<col width="27.8%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">Â <span class="Bold">Outcome Classification</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <span class="Bold">Fluvoxamine (N = 38)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">Â <span class="Bold">Placebo (N = 36)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  Very Much Improved </td>
<td class="Botrule Rrule" align="center" valign="top">Â  21% </td>
<td class="Botrule Rrule" align="center" valign="top">Â  11% </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  Much Improved </td>
<td class="Botrule Rrule" align="center" valign="top">Â  18% </td>
<td class="Botrule Rrule" align="center" valign="top">Â  17% </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  Minimally Improved </td>
<td class="Botrule Rrule" align="center" valign="top">Â  37% </td>
<td class="Botrule Rrule" align="center" valign="top">Â  22% </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â  No Change </td>
<td class="Botrule Rrule" align="center" valign="top">Â  16% </td>
<td class="Botrule Rrule" align="center" valign="top">Â  44% </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">Â  Worse </td>
<td class="Rrule" align="center" valign="top">Â  8% </td>
<td class="Botrule Rrule" align="center" valign="top">Â  6% </td>
</tr>
</tbody>
</table>
<p>Post hoc exploratory analyses for gender effects on outcomes did not suggest any differential responsiveness on the basis of gender. Further exploratory analyses revealed a prominent treatment effect in the 8 to 11 age group and essentially no effect in the 12 to 17 age group. While the significance of these results is not clear, the 2 to 3 fold higher steady-state plasma fluvoxamine concentrations in children compared to adolescents (see <span class="Bold">CLINICAL</span><span class="Bold">PHARMACOLOGY</span>, <span class="Bold">Pediatric Subjects</span> [<a href="#LINK_cd4f2edb-8d42-43c1-8097-b3f97a4634f7">12.3</a>]) is suggestive that decreased exposure in adolescents may have been a factor, and dose adjustment in adolescents (up to the adult maximum dose of 300 mg) may be indicated to achieve therapeutic benefit. </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_35238251-3142-48da-96ee-0fbc55bdf1d8"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c3cefa3a-6b5d-41e3-b367-0e65f017493a"></a><a name="section-15.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First">Fluvoxamine maleate tablets USP, 100 mg are available as pink to light-brick, film-coated capsule-shaped tablets debossed â€œ93â€? on one side and scored between the two numbers, and are debossed â€œ57â€? on the other side. They are available in blisterpacks of 30 tablets.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f1521fc4-d6b1-43fe-9e94-2dba4d4e94f2"></a><a name="section-15.2"></a><p></p>
<h2>16.2 Storage</h2>
<p class="First">Store at 20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled Room Temperature]. Protect from high humidity.</p>
<p>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</p>
<p>Keep this and all medications out of the reach of children.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_32dbf4a7-411b-43a9-b7e1-7034217504e7"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with fluvoxamine maleate tablets and should counsel them in the appropriate use. A patient Medication Guide about â€œ<span class="Bold">Antidepressant Medicines, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and other Serious Mental Illnesses, and Suicidal</span><span class="Bold">Thoughts or Actions</span>â€? is available for fluvoxamine maleate tablets. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document. </p>
<p>Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking fluvoxamine maleate tablets. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f95583ff-7df7-4d5e-811e-8968f61e6b0c"></a><a name="section-16.1"></a><p></p>
<h2>17.1 Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</h2>
<p class="First">Patients, their families, and their caregivers should be encouraged to be alert to the emergence of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, impulsivity, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">psychomotor restlessness</span>), <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, other unusual changes in behavior, worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be advised to look for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patientâ€™s prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patientâ€™s presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate the need for very close monitoring and possibly changes in the medication (see BOXED WARNING and <span class="Bold">WARNINGS AND PRECAUTIONS</span> [<a href="#LINK_6e4d7b0d-4f91-48a9-a17c-a75415c80d10">5.1</a>]). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_435096e7-461f-4a30-a1dc-9fdeaae454d4"></a><a name="section-16.2"></a><p></p>
<h2>17.2 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></h2>
<p class="First">Patients should be cautioned about the risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with the concomitant use of fluvoxamine and triptans, tramadol, or other serotonergic agents (see <span class="Bold">WARNINGS AND</span><span class="Bold">PRECAUTIONS</span>, <span class="Bold"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> or <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)-Like Reactions</span> [<a href="#LINK_63c287fc-8a3a-4736-9d90-e2b4c0573137">5.3</a>]). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f569dafa-8fd6-4549-bc7d-562ac1b069ec"></a><a name="section-16.3"></a><p></p>
<h2>17.3 Interference With Cognitive or Motor Performance</h2>
<p class="First">Since any psychoactive drug may impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are certain that fluvoxamine maleate tablet therapy does not adversely affect their ability to engage in such activities. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4a0a0daf-aa7a-4457-aa9d-338a2032615c"></a><a name="section-16.4"></a><p></p>
<h2>17.4 Pregnancy</h2>
<p class="First">Patients should be advised to notify their physicians if they become pregnant or intend to become pregnant during therapy with fluvoxamine maleate tablets (see <span class="Bold">USE IN SPECIFIC</span><span class="Bold">POPULATIONS</span> [<a href="#LINK_4d42ec68-2e52-4496-9a7c-4127291a917b">8.1</a>]). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_061ed931-9fe0-45cd-bf4a-d50163e5f2c6"></a><a name="section-16.5"></a><p></p>
<h2>17.5 Nursing</h2>
<p class="First">Patients receiving fluvoxamine maleate tablets should be advised to notify their physicians if they are breast-feeding an infant (see <span class="Bold">USE IN SPECIFIC POPULATIONS</span>, <span class="Bold">Nursing Mothers</span> [<a href="#LINK_0c47abe1-d82e-402d-a20d-18d400e5b133">8.3</a>]). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e08daa76-9f83-400d-a4a6-6849faaad0cb"></a><a name="section-16.6"></a><p></p>
<h2>17.6 Concomitant Medication</h2>
<p class="First">Patients should be advised to notify their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs, since there is a potential for clinically important interactions with fluvoxamine maleate tablets. </p>
<p>Patients should be cautioned about the concomitant use of fluvoxamine and NSAIDs, aspirin, or other drugs that affect coagulation since the combined use of psychotropic drugs that interfere with serotonin reuptake and these agents has been associated with an increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (see <span class="Bold">WARNINGS AND PRECAUTIONS</span>, <span class="Bold"><span class="Italics">Warfarin and Other Drugs That Interfere With</span></span><span class="Bold"><span class="Italics">Hemostasis</span></span> [<a href="#LINK_a38970d6-c303-4089-bf6e-49f0f281a2bb">5.8</a>]). </p>
<p>Because of the potential for the increased risk of serious adverse reactions including severe lowering of blood pressure and sedation when fluvoxamine and tizanidine are used together, fluvoxamine should not be used with tizanidine (see <span class="Bold">WARNINGS AND PRECAUTIONS</span> [<a href="#LINK_8581f9ea-ef79-4529-8aa2-84d6410677e9">5.5</a>]). </p>
<p>Because of the potential for the increased risk of serious adverse reactions when fluvoxamine and alosetron are used together, fluvoxamine should not be used with LotronexÂ® (alosetron) (see <span class="Bold">WARNINGS AND PRECAUTIONS</span> [<a href="#LINK_51997691-e6f7-4af2-86bc-875010a13dc6">5.7</a>]). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_fe36329d-38d4-44ce-bb41-ea4df847b5a4"></a><a name="section-16.7"></a><p></p>
<h2>17.7 Alcohol</h2>
<p class="First">As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c1bc49a9-7136-4364-9652-4babcc50bf73"></a><a name="section-16.8"></a><p></p>
<h2>17.8 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First">Patients should be advised to notify their physicians if they develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, or a related allergic phenomenon during therapy with fluvoxamine maleate tablets. </p>
<p>Lotronex<span class="Sup">Â®</span> is a registered trademark of GlaxoSmithKline.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7f794cbc-fc6a-47bd-ac2d-4d256767a3fe"></a><a name="section-16.9"></a><p></p>
<h2>17.9 FDA-Approved Medication Guide</h2>
<p class="First"><span class="Bold">Medication Guide</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="LINK_0922626c-000c-42bb-afda-68710f157c57"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Antidepressant Medicines, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and other Serious Mental Illnesses, and Suicidal Thoughts or Actions</span></p>
<p><span class="Bold">Rx only</span></p>
<p>Read the Medication Guide that comes with your or your family memberâ€™s antidepressant medicine. This Medication Guide is only about the risk of suicidal thoughts and actions with antidepressant medicines. <span class="Bold">Talk to your, or your family memberâ€™s, healthcare provider about:</span></p>
<ul class="Disk">
<li>all risks and benefits of treatment with antidepressant medicines</li>
<li>all treatment choices for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or other serious mental illness</li>
</ul>
<p><span class="Bold">What is the most important information I should know about antidepressant medicines, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and other serious mental illnesses, and suicidal thoughts or actions?</span></p>
<p><span class="Bold">1. Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment.</span></p>
<p><span class="Bold">2. <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a particularly high risk of having suicidal thoughts or actions.</span> These include people who have (or have a family history of) bipolar illness (also called <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span>-<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive illness</span>) or suicidal thoughts or actions.</p>
<p><span class="Bold">3. How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?</span></p>
<ul class="Disk">
<li>Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed.</li>
<li>Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings.</li>
<li>Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms.</li>
</ul>
<p><span class="Bold">Call a healthcare provider right away if you or your family member has any of the following symptoms, especially if they are new, worse, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you:</span></p>
<ul class="Disk">
<li>thoughts about <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> or dying</li>
<li>attempts to commit <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span></li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span></li>
<li>feeling very <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> or <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span></li>
<li><span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span></li>
<li>trouble sleeping (<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>)</li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span></li>
<li>acting aggressive, being angry, or violent</li>
<li>acting on dangerous impulses</li>
<li>an extreme increase in activity and talking (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>)</li>
<li>other unusual changes in behavior or mood</li>
</ul>
<p><span class="Bold">What else do I need to know about antidepressant medicines?</span></p>
<ul class="Disk">
<li>
<span class="Bold">Never stop an antidepressant medicine without first talking to a healthcare provider.</span> Stopping an antidepressant medicine suddenly can cause other symptoms.</li>
<li>
<span class="Bold">Antidepressants are medicines used to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and other illnesses.</span> It is important to discuss all the risks of treating <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and also the risks of not treating it. Patients and their families or other caregivers should discuss all treatment choices with the healthcare provider, not just the use of antidepressants.</li>
<li>
<span class="Bold">Antidepressant medicines have other side effects.</span> Talk to the healthcare provider about the side effects of the medicine prescribed for you or your family member.</li>
<li>
<span class="Bold">Antidepressant medicines can interact with other medicines.</span> Know all of the medicines that you or your family member takes. Keep a list of all medicines to show the healthcare provider. Do not start new medicines without first checking with your healthcare provider.</li>
<li>
<span class="Bold">Not all antidepressant medicines prescribed for children are FDA approved for use in children.</span> Talk to your childâ€™s healthcare provider for more information.</li>
</ul>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</span></p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration for all antidepressants.</p>
<p>Lotronex<span class="Sup">Â®</span> is a registered trademark of GlaxoSmithKline. </p>
<p>Manufactured In Israel By:</p>
<p><span class="Bold">TEVA PHARMACEUTICAL IND. LTD.</span></p>
<p>Jerusalem, 91010, Israel</p>
<p>Manufactured For:</p>
<p><span class="Bold">TEVA PHARMACEUTICALS USA</span></p>
<p>Sellersville, PA 18960</p>
<p>Rev. R 3/2009</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_47958592-1e3a-4053-9c2e-5e2381253a22"></a><a name="section-18"></a><p></p>
<h1><span class="Bold">PRINCIPAL DISPLAY PANEL</span></h1>
<p class="First">Fluvoxamine Maleate Tabs,</p>
<p>USP 100mg</p>
<div class="Figure"><img alt="Principal Display Panel - Fluvoxamine Maleate 100mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=727a5eb4-ac82-444d-8381-44c34ee3b895&amp;name=fluvoxamine-maleate-2.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FLUVOXAMINE MALEATEÂ 		
					</strong><br><span class="contentTableReg">fluvoxamine maleate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0615-7569(NDC:0093-0057)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FLUVOXAMINE MALEATE</strong> (FLUVOXAMINE) </td>
<td class="formItem">FLUVOXAMINE MALEATE</td>
<td class="formItem">100Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STEARYL FUMARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK (pink to light-brick) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule-shaped tablets) </td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">9;3;57</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0615-7569-39</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA075893</td>
<td class="formItem">03/12/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>NCS HealthCare of KY, Inc dba Vangard Labs
							(050052943)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NCS HealthCare of KY, Inc dba Vangard Labs</td>
<td class="formItem"></td>
<td class="formItem">050052943</td>
<td class="formItem">RELABEL(0615-7569), REPACK(0615-7569)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>37c5c6bd-6df6-4f8c-b7f1-c19bb8d8243e</div>
<div>Set id: 727a5eb4-ac82-444d-8381-44c34ee3b895</div>
<div>Version: 4</div>
<div>Effective Time: 20130304</div>
</div>
</div>Â <div class="DistributorName">NCS HealthCare of KY, Inc dba Vangard Labs</div></p>
</body></html>
